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Abstract 
There are multiple copies of mtDNA per cell and each mtDNA molecule contains 
the information to encode 13 electron transport chain (ETC) proteins. When mtDNA is 
depleted, there is a decrease in ETC activity. 5' AMP-activated protein kinase (AMPK) is 
a kinase that can initiate mitochondrial biogenesis and mitophagy. We hypothesized that 
treating cells harbouring low numbers of mtDNA with an AMPK activator (5-
Aminoimidazole-4-carboxamide ribonucleoside; AICAR) would ameliorate the decrease 
in ETC activity and improve mtDNA copy number. We developed myoblasts (C2C12 
cells) depleted of mtDNA with long-term ethidium bromide treatment. We treated 
selected clones for 24 hours with 1 mM AICAR to activate AMPK. AICAR treatment 
decreased markers of mitochondrial biogenesis, mitochondrial function (e.g. maximal 
cellular respiration), and mitochondrial degradation. Thus, failing to increase the energy 
producing capacity of the cell, activation of AMPK may have induced an energy sparing 
mechanism.  
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Review of Literature 
1. Mitochondrial DNA 
Among mammalian organelles, mitochondria are distinct because, other than the 
nucleus, they are the only organelle to contain genetic material. According to the 
endosymbiotic theory, mitochondrial DNA (mtDNA) is a remnant of DNA contained 
within prokaryotic organisms that were engulfed by early eukaryotic cells (1). 
Mitochondria are the main source of energy for mammalian cells. Within mitochondria, 
the tricarboxylic acid (TCA) cycle and the electron transport chain (ETC) coordinately 
produce adenosine triphosphate (ATP) – the cellular form of energy. The presence of 
mtDNA remains necessary to mitochondria, as it encodes gene products essential for the 
production of the ETC and ATP Synthase. 
Akin to the nuclear genome, mutagens and free radicals can manipulate the 
mitochondrial genome. Directly and indirectly, these mutations are associated with 
common diseases, such as Parkinson’s disease, Alzheimer’s disease, and diabetes 
mellitus (2). In the late 1980s, mutations in mtDNA were identified as the origin of 
unique metabolic diseases (3). For these reasons, mtDNA is a source of great mystery 
and interest both at the basic and applied research levels. 
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1.1. Characteristics and Structure 
In mammals, mtDNA is a circular, double-stranded DNA molecule. Human 
mtDNA is 16.6 kb long with a large non-coding region (NCR) and genes encoding 13 
peptides, 22 tRNAs and 2 rRNAs (Fig. 1a; 4-6). These peptides include 7 subunits of 
NADH Dehydrogenase, 1 subunit of Cytochrome bc1, 3 subunits of Cytochrome C 
Oxidase (COX), and 2 subunits of ATP Synthase. No subunits of Succinate 
Dehydrogenase (i.e. Complex II of the ETC) are encoded by mtDNA. Each strand of 
mtDNA contains unique characteristics. The heavy strand (H-Strand) encodes the 
majority of mtDNA genes, including 12 peptides, 16 tRNAs and 2 rRNAs. It is named 
the heavy strand because it is relatively guanine-rich and consequently has a greater 
molecular weight. The light strand (L-strand) encodes 1 peptide and 8 tRNAs and 
comprises the relatively lighter strand abundant with cytosine nucleotides. The Non-
Coding Region (NCR) contains important regulatory sequences and DNA structures 
including 3 hypervariable regions, the H-strand replication origin (OH), the bidirectional 
replication origin (Orib), 3 conserved sequence blocks (CSB), the heavy-strand promoter 
1 (HSP1), the light-strand promoter (LSP) and the displacement loop (D-Loop; Fig. 1a; 
(6). The D-Loop is a unique triple-stranded region within the NCR. The majority of 
variability in the human mtDNA genome is within the NCR and is primarily focused 
within the hypervariable regions (6). 
Multiple mtDNA molecules are contained in each mitochondrion and an estimated 
103 – 104 copies of mtDNA exist in each somatic mammalian cell (7). These mtDNA 
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molecules are organized into structures, called nucleoids, by accessory proteins (8). 
Mitochondrial transcription factor A (TFAM) is the most abundant nucleoid protein. 
High-resolution microscopy has revealed that TFAM induces U-turns in mtDNA (9). 
Unfolded mtDNA has a diameter of 5 µm. Each nucleoid compacts the 5 µm diameter 
mtDNA into an estimated 100 nm diameter complex (8). Originally, it was estimated that 
2-10 mtDNA molecules were contained within each nucleoid. However, recent studies 
suggest each nucleoid contains an average of 1.45 mtDNA molecules (10).  
It is important to note that the size and shape of mtDNA and the distribution of 
mtDNA genes vary between species. Many organisms, such as Tetrahymena pyriformis 
and Saccharomyces cerevisiae, contain linear mtDNA (11). Even within the mammalian 
class, mtDNA can vary in length. For example, bovine mtDNA is only 16.3 kb long (12). 
1.2. Mitochondrial DNA Replication and Transcription 
The replication and transcription processes of mtDNA are inherently intertwined. 
Traditionally, it is believed that before replication can occur, transcription must begin 
and provide the primers required for the subsequent replication. 
1.2.1. Mitochondrial DNA Replication 
Many aspects of mtDNA replication remain greatly debated or poorly understood 
(6). These aspects include the components of the mtDNA copying machinery, the overall 
mechanism of mtDNA duplication, and the origin of mtDNA replication. 
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The prevailing dogma among mitochondrial research is that the main mtDNA 
replisome comprises of Twinkle, mitochondrial single stranded binding protein (mtSSB) 
and polymerase gamma (POLγ; Fig. 1b). This is a result of in vitro studies that have 
demonstrated these as the minimum required proteins for mtDNA duplication (13). POLγ 
is a heterotrimeric protein composed of an α and 2 β subunits. Currently, POLγ is the 
only mitochondrial DNA polymerase known in humans. Although others have suggested 
other DNA polymerases likely exist, none have yet to be identified (6). POLγ is unable to 
replicate double stranded mtDNA (6). Therefore double stranded mtDNA must be 
unraveled by the DNA helicase, Twinkle. This produces single stranded mtDNA for 
POLγ to replicate (14). Overexpression of Twinkle has been shown to increase novel 
mtDNA synthesis (15). mtSSB binds and stabilizes the newly synthesized single stranded 
DNA. Its presence extends the maximum length of double stranded DNA replicated by 
POLγ and Twinkle to ~16 kb from 2 kb (16) and thus suggests its crucial role in DNA 
replication. Another protein important for mtDNA replication is Mitochondrial 
Transcription Termination Factor (MTERF1). MTERF1 binds mtDNA and slows 
mtDNA synthesis (17). This is believed to reduce the rate of misincorporated nucleotides. 
Overall, in vitro with only POLγ, Twinkle and mtSSB, mtDNA synthesis occurs at rate 
of 180 BP/min. In vivo, mtDNA is estimated to synthesize at 270 BP/min (16). 
Currently, there are two major competing theories of mtDNA replication (6, 18). It 
is believed both are accurate and do occur. Both share initiation through binding of RNA 
primers to either the OH or Orib sites. For a thorough review of mtDNA replication 
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theories and evidence, the reader is directed to (Holt et al. 2012; 6). Briefly, mtDNA 
replication was originally believed to occur in a strand-displacement mechanism (SDM; 
Fig. 1b). In this theory, the replication of the heavy-strand originates at the OH producing 
a long single-stranded DNA molecule, termed the leading-strand. Concurrently, multiple 
mitochondrial single-stranded DNA binding proteins (mtSSB) bind the displaced light-
strand or lagging-strand. Replication continues until the machinery reaches the OL. Upon 
reaching the OL, replication of the light-strand begins in the opposite direction, 
replicating the light-strand and producing the complement to the lagging-strand. 
The major competing theory to the SDM is the Ribonucleotide Incorporation 
Throughout the Lagging Strand (RITOLS) theory (Fig. 1b; 19). According to the 
RITOLS theory, mtDNA replication initiates at either the OH or the Orib. However, as the 
leading-strand is generated, RNA intermediates are produced and stabilize the displaced 
L-strand. These RNA intermediates are then either replaced or converted to DNA to 
create a nascent mtDNA molecule. Also, there is some evidence for a nuclear DNA- 
(nDNA) like strand-coupled mechanism for replicating mtDNA (6, 20). 
Research has demonstrated multiple origins of replication. The most recognized is 
the OH site at nucleotide 191 of human mtDNA (6). Replication of the H-strand continues 
in a clockwise direction from this point. Approximately two-thirds of the way around the 
mtDNA molecule lays the second origin of replication (OL). A second origin of 
replication has been identified in the NCR. This replication origin (Orib) is able to initiate 
replication bi-directionally (21). The reasons for 2 origins in the NCR are unknown. 
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Figure 1. mtDNA replication and transcription. A) Representation of a single mtDNA 
molecule with the genes for the 13 peptides, 22 tRNAs, and 2 rRNAs labeled. Also 
included are the three origins of replication – OH, Orib, and OL, the light strand promoter 
(LSP), the heavy strand promoter (HSP), conserved sequence blocks (CSBs), Non-Coding 
Region (NCR), and the displacement loop (D-Loop). B) Depiction of two models of 
mtDNA replication. In both models Twinkle unravels mtDNA and POLγ binds to one 
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by mtSSB in the strand-displacement model or by temporary RNA strands in the RITOLS 
model. C) The 3-component transcriptional machinery model consists of TFAM, TFB2M, 
and POLMRT. Transcription proceeds from a promoter (e.g. LSP) and proceeds in a 5’ to 
3’ direction. 
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1.2.2. Mitochondrial DNA Transcription 
Similar to mtDNA replication, mtDNA transcription has been extensively studied 
but remains poorly understood. mtDNA transcription has been reproduced in vitro, albeit 
not without difficulty (22). A reported 6-12 liters of KB (derivatives of HeLa cells) cells 
were required to reproduce mtDNA transcription and likely limited early research into 
the topic. 
There remains a debate about the required machinery for transcription (23). A 
prevailing mechanism suggests that mtDNA transcription only requires mitochondrial 
transcription factor B2 (TFB2M) and mitochondrial RNA polymerase (POLMRT; 24). 
Alone TFB2M and PLMRT are able to initiate mtDNA transcription at all three of the 
identified mtDNA promoter regions (LSP, HSP1 and HSP2; 23). The competing theory 
suggests that mitochondrial transcription factor A (TFAM) is also required. Studies show 
that the presence of TFAM increases the rate of transcription initiating at LSP and HSP1, 
in a concentration-dependent manner (24). However, TFAM appears to decrease the rate 
of transcription at HSP2 (25). Some evidence suggests that transcription at HSP1 
preferentially produces transcripts coding only the rRNA and acts to maintain the higher 
amount of rRNA versus mRNA required for translation (26). Other proteins that regulate 
mtDNA transcription include the MTERF family (MTERF1-4), the mitochondrial 
Leucine-Rich Pentatricopeptide Repeat Containing protein, the Mitochondrial Ribosomal 
Protein 12, and the Mitochondrial Transcription Elongation Factor (TEFM; 23). 
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Promoters for mtDNA have been long predicted to exist within the NCR (23). 
Indeed, the LSP and HSP1 are within the NCR. However, the more recently identified 
HSP2 is located within the coding region for 12S rRNA (26). As mentioned above, 
TFAM appears to regulate which promoters are actively transcribed. 
 Conventionally, mtDNA transcription is believed to generate polycistronic 
transcripts of the entire H-strand and L-strand coding regions (23). These long transcripts 
are then post-transcriptionally processed to generate individual mRNAs, tRNAs, and 
rRNAs. Current research has suggested that this may not be the case. Transcription 
initiating at HSP2 and LSP produce the long polycistronic transcripts previously observed. 
However, transcription initiated at the HSP1 appears to terminate just past the rRNA 
coding regions (26). 
1.3. Fidelity Regulation 
The maintenance of mtDNA is critical to cellular function. Mutations and deletions 
of mtDNA result in severe cellular dysfunction and disease. In 2005, Kujoth et al. created 
a mouse model of mtDNA dysfunction (27). This mouse, hereafter denoted as the POLγ 
Mutator mouse, has a mutation in the Polg1 gene that disables the exonuclease activity of 
POLγ. This impairs POLγ’s proofreading ability and results in the accumulation of 
mtDNA mutations throughout the decreased life span of the organism. The dysfunctional 
POLγ results in increased levels of apoptosis, kyphosis, and many other symptoms. This 
emphasizes the importance of maintaining mtDNA fidelity to the survival and function of 
organisms. 
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The maintenance of mtDNA fidelity begins with proper the replication of mtDNA. 
POLγ incorporates the wrong nucleotide an estimated 1 in every 250,000 base pairs (28). 
This low rate of errors may be a result of the inherent proofreading ability of POLγ and 
the MTERF family of proteins. MTERFs are believed to slow mtDNA replication to 
enable accurate nucleotide sequence polymerization (17). However, if POLγ makes a 
mistake, other processes can be invoked to maintain the genome’s integrity. 
DNA repair mechanisms in mitochondria were believed to be far less extensive 
than those of the nucleus. Early evidence demonstrated that mitochondria are capable of 
nucleotide excision repair. This process occurs in 4 steps (29): (1) removal of the 
damaged DNA base and DNA cleavage, (2) processing of the cleaved DNA, (3) gap 
filling, and (4) ligation. The first two steps of this pathway are performed by 
monofunctional glycosylases with AP endonuclease 1 (APE1) and bifunctional 
glycocsylases, such as 8-oxoguanine-DNA glycosylase 1 (OGG1; 29, 30). POLγ then 
completes the gap filling process by inserting the appropriate nucleotide (31). Finally, 
DNA ligase 3 (LIG3) connects the DNA fragments (29). Evidence suggests that p53, a 
tumor suppressor protein, can translocate to the mitochondria of a cell and assist in 
mtDNA repair under certain conditions (29). 
Recently, proteins of nuclear DNA repair pathways have been observed in 
mitochondrial fractions and suggest that mtDNA repair may be much more extensive 
than previously thought (29). Mismatch repair (MMR) was originally identified in rat 
liver mitochondrial lysate (32). Not much is known about MMR in the mitochondrion, 
 10 
but it is believed that it does not share the same protein machinery as nuclear MMR (29). 
Single-stranded and double-stranded DNA break repair have also been observed (29). It 
is suggested the mechanism may be similar to homologous recombination observed in 
nDNA. Another unique aspect of mitochondrial DNA maintenance is the ability to 
degrade mtDNA. Unlike nDNA, mtDNA exists in multiple copies and, if catastrophic 
damage occurs, a single copy of mtDNA could be degraded without a significant effect 
on cell homeostasis. Additionally, other work has also suggested that a “bottleneck” 
exists, where mtDNA mutations can be selected against during embryonic development 
(33). Furthermore, there is evidence that mtDNA containing large deletions and specific 
mutations actually provide a replicative advantage, so that the degradation of these 
mtDNA molecules could indeed be necessary, to prevent accumulation of incomplete or 
error filled mtDNA (6). The main endonuclease in mitochondria is Endonuclease G 
(EndoG; 29). EndoG is also released from the mitochondria to fragment nDNA during 
apoptosis (34). 
Novel evidence has added another disconnect in our understanding of mtDNA 
fidelity regulation. Mitochondria are dynamic organelles that continually undergo fission 
and fusion to maintain a reticular network. Mitofusin proteins (mitofusin 1 – Mfn1 and 
mitofusin 2 – Mfn2) regulate outer mitochondrial membrane fusion (35, 36). In skeletal 
muscle, genetic ablation of these proteins results in an increase in the number of mtDNA 
mutations observed and a decrease in mitochondrial DNA copy number (37, 38). Thus, 
there may be a connection between organelle dynamics and the genomic stability. 
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1.4. Mitochondrial DNA Copy Number 
Numerous copies of mitochondrial DNA exist per cell, and this number is highly 
regulated. In humans, Mitochondrial Depletion Syndrome (MDS) is the result of a lower 
than normal number of mtDNA molecules. Furthermore, a study has identified that as 
much as 18% of electron transport chain deficiencies observed in children are associated 
with MDS (39). Additionally, Durham et al. found that the average mtDNA density was 
0.0039 mtDNA/um3 in skeletal muscle from patients with MDS versus 0.0825 - 0.220 
mtDNA/um3 healthy controls (40). This corresponded to COX deficient fibers in the 
patients, although some fibers with 0.01 – 0.015 mtDNA/um3 still maintained some COX 
activity. Thus, there may be a critical threshold for mtDNA required maintenance of ETC 
enzyme activity and mtDNA copy number is critical to oxidative phosphorylation and 
cellular homeostasis. However, the mechanism regulating mitochondrial DNA copy 
number is not known. 
It has been long known that mtDNA copy number can be manipulated by the use of 
DNA intercalating agents, particularly Ethidium Bromide (EtBr; 41). This has been an 
invaluable tool in mitochondrial and mtDNA research. Because it is positively charged, 
EtBr preferentially accumulates in the negatively charged matrix of mitochondria. Thus, 
at low levels EtBr is believed to specifically affect mtDNA (42). Acute treatment (less 
than 15 days) with DNA intercalating agents produces cells partially depleted of mtDNA 
(ρ- cells; 41). In 143B.TK- cells, chronic treatment can completely abolish mtDNA, 
resulting in ρ0 cells (43). Innoue et al. suggested C2C12 cells have a resistance to 
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mtDNA depletion by EtBr and that another intercalating agent, ditercalinium, is more 
effective (44). However, many researchers have successfully employed longer treatments 
of EtBr (greater than 6 weeks) to create ρ- C2C12 cells (45). This might suggest that 
mtDNA is so critical to C2C12 survival that this cell line expresses factors that make it 
particularly resistant to mtDNA depletion.  
Studies have investigated the role specific proteins have on mtDNA copy number. 
In humans, mtDNA depletion can result from mutations in genes essential for mtDNA 
replication (e.g. Polg1, Polg2 and C10orf2 – Twinkle) and mitochondrial dNTP supply 
(e.g. Mitochondrial Deoxyguanosine Kinase; DGUOK, Thymidine Kinase 2; TK2, and 
Thymidine Phosphorylase; TYMP; 46). Transgenic mice with a homozygous ablation of 
TFAM, C10orf2, Polg1, and Polg2 (the accessory subunit of POLγ) all die during 
embryonic development between ~E8.5 and 10.5 (47-50). Analysis revealed no or very 
little (approximately < 5% of wildtype levels) mtDNA in TFAM-/-, Polg1-/-, and Polg2-/- 
animals. In contrast, transgenic mice overexpressing Twinkle and TFAM protein 
maintain higher levels of mtDNA (14, 51). The levels of Twinkle protein in these mice 
directly correlated with the mtDNA copy number (14). When Twinkle and TFAM were 
simultaneously overexpressed an additional increase in mtDNA copy number occurred, 
suggesting independent regulation of mtDNA copy number (15). This effect was 
suggested to be a result of Twinkle’s role in de novo synthesis of mtDNA and TFAM’s 
role in mtDNA stabilization. However, the authors suggested that too much mtDNA 
could also be detrimental to the organism. T
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appearance of cytochrome c oxidase (COX) deficient muscle fibers (15). Surprisingly, 
ablating TFB1M results in an increase in mtDNA, perhaps through a compensatory 
increase in TFAM expression (52). This evidence all indicates the critical role these 
proteins play in mtDNA copy number regulation. 
1.5. Mitochondrial DNA Disorders 
Approximately 1 in 7,200 individuals are diagnosed with a mitochondrial disease 
due to mtDNA mutations (53). It has been suggested that this prevalence is 
underestimated due to the difficulty in diagnosing these disorders. This is supported by a 
study that found 1 in 200 newborns have a detectable level of pathological mtDNA in 
their umbilical cord blood (54). These diseases result in a wide array of phenotypes that 
can include hearing impairment, stroke-like episodes, ataxia, and exercise intolerance 
(55). Complicating the matter further, there are stark differences between tissues and 
even between patients with the same disease origin (56). This contributes to the difficulty 
in diagnosing these diseases and furthers the requirement for individual treatment of 
these diseases. 
1.5.1. Types and Origins 
mtDNA disease arises from alterations in many proteins that directly or indirectly 
affect mitochondria. These include mutations in both the nuclear and mitochondrial 
genome. 
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1.5.1.1. Nuclear Genes Causing mtDNA Diseases 
Nuclear DNA is acquired through Mendelian inheritance. It also possesses 
numerous repair pathways to prevent accumulation of potentially hazardous DNA 
damage. However, damage does occur and diseases such as cancer are a result. In the 
case of mtDNA disease, mutations in nuclear proteins required for the replication, 
transcription, and translation of mtDNA all cause mitochondrial disease. This can cause a 
loss of mtDNA, or mutations and deletions of mtDNA (27, 46, 57; Fig. 2). Mutations in 
many genes required for mtDNA replication (such as Polg1 and C10orf2) can produce 
diseases such as Autosomal Dominant Progressive External Opthalmoplegia (adPEO), 
where there is progressive weakening of external eye muscles (46, 57). 
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Figure 2. mtDNA disease origins. Mitochondrial DNA diseases can originate from both 
the mitochondrial and nuclear genome. mtDNA deletions can result in diseases 
including KSS and Pearson’s Syndrome. mtDNA mutations result in inherent diseases 
originating from the specific mutations, such as MELAS, MERRF, and LHON. 
Mutations in nDNA can cause defects in mtDNA replication resulting in a lack of 
mtDNA. This is called mtDNA Depletion Syndrome (MDS) and can also result in 
adPEO and Alper’s Syndrome. 
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1.5.1.2. Mitochondrial Sources of mtDNA mutations 
Mutations in mtDNA accumulate from exposure to oxidative stress, UV irradiation, 
and mutagens. The ETC is a significant source of cellular reactive oxygen species (ROS). 
During maximal respiration as much as 3% of total cellular oxygen is converted to ROS 
(58). Because of its proximity to the ETC, mtDNA is susceptible to oxidation by ROS. 
Early studies showed that the oxidized nucleic acid base, 8-hydroxydeoxyguanosine 
(oh8dG), was present once every 800 bases in mtDNA and only once every 130,000 
bases in the nuclear genome (59). These oxidized bases can then cause improper 
incorporation of the wrong nucleic acids during mtDNA transcription and replication 
(31). The effect of ROS on mtDNA is the core of the mitochondrial theory of aging, 
whereby ROS from the ETC causes mutations in the mtDNA and these mutations 
consequently cause creation of dysfunctional gene products from mtDNA leading to 
more ROS being produced and more oxidative damage to cellular components, such as 
cell membranes, proteins, and DNA (60). 
Specific diseases due to mutations or deletions of mtDNA have only been known 
for 25 years. In 1988, two laboratories simultaneously discovered the first mtDNA 
diseases – deletions of mtDNA present in patients with mitochondrial myopathies (61) 
and a point mutation causing Leber’s Hereditary Optic Neuropathy (LHON; 3). 
Identification of these diseases was facilitated by identification of a maternally inherited 
pedigree of morbidity. There are many mitochondrial myopathies currently recognized as 
originating from mutations or deletions in mtDNA. These include Leigh’s Syndrome 
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(LS), Kearns-Sayre Syndrome (KSS), Mitochondrial Encephalomyopathy with Lactic 
Acidosis and Stroke-Like Episodes (MELAS), Myoclonic Epilepsy with Ragged Red 
Fibers (MERRF), and Neuropathy Ataxia with Retinitis Pigmentosa (NARP; 62; Fig. 2).  
1.5.2. Effects 
The symptoms of mitochondrial myopathies are extremely tissue-dependent and 
patient-specific. These diseases are progressive in nature and result in a shortened 
lifespan. Since numerous copies of mtDNA exist, both wildtype and pathological 
mtDNA molecules can coexist in a cell in a state called heteroplasmy (62). Before 
symptoms present, pathological mtDNA must be expressed at a high enough level. The 
tolerable amount of mutated mtDNA before symptoms present is known to be tissue-
specific. For example, the A3243G mutation in mtDNA causes diabetes at low levels 
(40-50%), but can also cause PEO and MELAS with higher mutation loads, 60-70% and 
80-95%, respectively (63). Highly metabolic tissues, such as the heart, liver, skeletal 
muscle, and neurons, are particularly affected (62). For example, in skeletal muscle, 
massive dysfunctional mitochondria proliferate, accumulate at the sarcolemmal 
membrane, and produce ragged red fibers. In patients, these disorders can present with 
conditions such as extreme exercise intolerance, diabetes mellitus, ataxia, and hearing 
loss (62). 
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1.5.3. Potential Cures and Treatments 
To date, there are no cures for mitochondrial diseases. Clinical approaches mostly 
attend to secondary disorders caused by these diseases. Many theoretical therapies and 
cures have been demonstrated in cell culture and animal models. Only recently have 
studies investigated some of these treatments in patients. 
The genetic and pharmaceutical remedies in cell culture and animal models can be 
categorized into a) treatments that improve cellular function through compensatory 
mechanisms and b) those that replace or correct the mutant genetic material. Because of 
the importance of PGC-1α pathway to mitochondrial biogenesis (reviewed in section 2.1), 
many research groups have used overexpression of PGC-1α to improve mitochondrial 
function in models of mitochondrial disease. In fibroblasts from patients with mtDNA 
diseases, Srivastava et al. showed partial improvements in basal respiration when 
transduced with viruses overexpressing PGC-1α and PGC-1β (64). Although not directly 
affecting mtDNA, ablations of COX assembly factors – including COX10, Surf1, 
COX15 and Sco2 – are common models of mitochondrial disease. Skeletal muscle 
overexpression of PGC-1α slowed the onset of COX enzyme activity dysfunction in mice 
lacking COX10 (65), and improved COX enzyme activity in mice not expressing Surf1 
(66). Furthermore, researchers have investigated the use of drugs targeting the PGC-1α-
AMPK pathway. In cell culture, a study by Golubitzky et al., treated cells harbouring 
mutations in nuclear genes encoding NADH Dehydrogenase subunits with drugs shown 
to increase mitochondrial biogenesis, including resveratrol and 5-Aminoimidazole-4-
 19 
carboxamide ribonucleoside (AICAR; 67). They identified AICAR, an AMPK agonist, as 
the most beneficial small compound to cellular ATP and ROS levels. Other studies found 
that the PPAR panagonist, bezafibrate, elicited similar effects as PGC-1α overexpression 
on COX10-/- mice (65), but induced weight loss and massive amounts of apoptosis in 
Surf1-/- and COX15-/- mice respectively (66). However, AICAR was found to ameliorate 
the COX enzyme activity deficit in Surf1-/- mice, COX15-/- mice, and mice expressing a 
mutant form of Sco2ko/ki (66). This suggests that transgenic PGC-1α overexpression may 
assist in compensating for defects observed in mitochondrial disease, but drugs targeting 
this pathway are not a panacea for mitochondrial disease. 
Studies have shown that genetically targeting nuclear encoded RNAs to the 
mitochondria can compensate for mutated mtDNA encoded RNAs. Kolesnikova et al. 
first demonstrated that transducing a derivative of the yeast tRNALys into 
transmitochondrial cybrids, with the A8344G mutation, results in the import of the 
tRNALys into mitochondria (68). Furthermore, the tRNALys was able to improve 
mitochondrial respiration, mitochondrial membrane potential, and activities of the ETC 
complexes. More recently, laboratories have demonstrated that by attaching a sequence 
from the 3’ untranslated region (UTR) of human Mitochondrial Ribosomal Protein S12 
(MRPS12) mRNA, nuclear encoded tRNAs and larger mRNAs can be imported into 
mitochondria (69). In cybrids harbouring the A8344G and A3243G mutations, targeting 
of the tRNALys and tRNALeu, respectively, partially rescues cellular respiration (69). Thus, 
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targeting of nuclear tRNAs and mRNAs to the mitochondria may provide a method to 
essentially replace the mutated tRNAs and mRNAs in mtDNA diseases. 
Alternatively, a study has used exercise to improve mitochondrial dysfunction in a 
mouse model with mtDNA mutations. The POLγ mutator mouse has a mutation in the 
proofreading region of Polg1 gene that results in an accumulation of mtDNA mutations 
(27). With exercise, the pathologies, including increased levels of apoptosis, increased 
mtDNA mutations, and decreased mtDNA copy number, are reversed (70). This suggests 
that exercise is a potential therapy for diseases related to mutations in Polg1 and mtDNA 
mutations. 
A recent Cochrane review emphasized our dearth of knowledge of mitochondrial 
disease treatments. They found only 12 randomized-control trials of sufficient integrity to 
be considered (71). These studies supplemented patients with creatine (72-74); coenzyme 
Q10, creatine, and lipoic acid in combination (75); dichloroacetate (76-80); 
dimethylglycine (81), and cysteine (82). The reviewers found insufficient evidence to 
conclude that any of these treatments were beneficial. 
Other studies have investigated the use of exercise in patients with mitochondrial 
disorders. Improvements in VO2max, endurance performance, and muscle strength have 
all been observed (83, 84). Furthermore, mitochondrial proteins, such as cytochrome c, 
appear to increase similarly between patient and control individuals with training (85). 
However, no changes in mtDNA copy number were observed in patients with mtDNA 
deletions, suggesting the underlying cause of the disease remains present (84). Basic 
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scientific evidence suggests there are many potential therapies and cures for 
mitochondrial disease. However, more human studies must be completed before a 
resolution to mitochondrial disease can be found. 
  
 22 
2. Mitochondrial Content Regulation 
Mitochondria play a pivotal role in cell homeostasis. They are generators of 
intracellular energy but also regulators of cell death. Thus, maintaining a healthy 
mitochondrial pool is absolutely vital. Their function is mediated by either the growth of 
new mitochondria, or by the degradation of old and defective mitochondria.  
2.1. Mitochondrial Biogenesis 
Mitochondrial biogenesis is the process by which a cell attains more mitochondrial 
content. Unlike traditional textbook depictions of the organelle, mitochondria actually 
form a dynamic reticulum reaching throughout the cell. Therefore mitochondrial 
biogenesis is more than the growth of new discrete mitochondria, but rather the 
expansion of this organelle network. This process requires expansion of both the inner 
and outer mitochondrial membranes (IMM and OMM, respectively), and the creation and 
import of proteins (Fig. 3). 
2.1.1. Mitochondrial Membrane Synthesis 
Mitochondrial membranes play a critical role in mitochondrial homeostasis. The 
OMM defines the outer border of a mitochondrion. The OMM can undergo fission, via 
the action of Drp1 and Fis1, and fusion with other mitochondria, through Mfn1 and Mfn2 
(86). The IMM houses the key components of the ETC and thus plays a vital role in 
oxidative energy production. Mitochondrial membranes have unique lipid composition 
profiles that are different between the IMM and OMM. For example, rat liver IMMs 
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contain 14-23% cardiolipin (CL), 32-39% phosphatidylethanolamine (PE), 28-45% 
phosphatidylcholine (PC), and 2-7% phosphatidylinositol (PI), versus rat liver OMMs 
that contain 3-10% CL, 20-35% PE, 38-45% PC, and 5-20% PI (87, 88). However, the 
synthesis, import, and localization mechanisms for these lipids are poorly understood. 
Many phospholipids are synthesized in the mitochondria, including CL and PE, but PC 
and PI are primarily synthesized in the ER (87, 88). CL is a key phospholipid for 
mitochondrial function. It comprises 18% of phospholipids in rat liver mitochondria (88, 
89). Mutations in the gene encoding Taffazin, a key protein in CL synthesis, cause Barth 
syndrome (89, 90). Barth syndrome is characterized by dilated cardiomyopathy, skeletal 
myopathy, and infantile death in males (90-92). The severity of this disease may be due 
to the diverse role of CL in mitochondrial homeostasis. CL is known to assist in the 
stabilization and activity of Complex III and IV of the ETC (87, 91, 92). Also, CL 
participates in mitochondrial protein import (87, 93, 94) and regulates mitochondrial-
mediated apoptosis by binding cytochrome c (93-95). Although the mechanisms of 
mitochondrial phospholipid synthesis are poorly understood, it appears they are critical 
for the organelle’s function. 
2.1.2. Mitochondrial Protein Synthesis 
There are an estimated 1,100-1,400 proteins in human mitochondria and mtDNA, 
as described previously (section 1), encodes only 13 of these peptides (95). Nuclear 
genes encoding mitochondrial destined proteins are called nuclear genes encoding 
mitochondrial proteins (NUGEMPs). Despite the mitochondrion’s enormous proteome, 
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Peroxisome Proliferator-Activated Receptor Gamma Co-Activator 1-alpha (PGC-1α) 
appears to regulate much of the NUGEMP expression and is thus called the “master 
regulator of mitochondrial biogenesis” (97). PGC-1α is a transcriptional co-activator. It 
binds transcription factors containing a LXXLL motif, promoting their activity, and 
remodels chromatin to increase transcription of genes related to mitochondrial biogenesis. 
PGC-1α is upregulated under many conditions, including cold-exposure and exercise 
training – a common stimulus to increase mitochondrial content (Fig. 3). However, mice 
that lack PGC-1α are viable and do contain mitochondria. Although, these mitochondria 
are less functional, and the mice experience attenuated mitochondrial biogenesis (98). 
Some of this may be explained through compensatory increases in other PGC-1α family 
members, including PGC-1β (99) and PGC-1α Related Co-Activator (PRC; 100), which 
share some of PGC-1α’s activity. 
PGC-1α is able to induce a transcriptional cascade leading to mitochondrial protein 
synthesis. Specifically, PGC-1α induces the transcription of Nuclear Receptor Factors-1 
and -2 (NRF-1 and NRF-2) and Estrogen-Related Receptor alpha (ERRα; 97). NRF-1 is 
able to consequently increase the expression of TFAM and thus, PGC-1α coordinates the 
transcription of both the nuclear and mitochondrial genome for mitochondrial biogenesis 
(Fig. 3). 
2.1.3. Protein Import Into the Mitochondria 
After NUGEMPs are transcribed and translated into mitochondrial-destined 
proteins, they must be imported into the mitochondria (Fig. 3). Proteins are targeted for 
 25 
import by a mitochondrial targeting sequence (MTS), which is most commonly found at 
the N-terminus (101). However, there is no consensus on the MTS sequence, although, 
an algorithm exists that can use the amino acid sequence of a protein to predict the 
likelihood of mitochondrial localization (102). When entering a mitochondrion, proteins 
must be channeled to the appropriate compartment, such as the matrix, IMM, 
intermembrane space, or OMM (101). This import is achieved through a variety of 
protein import machineries (101). Protein transfer through the OMM is achieved by the 
Translocase of the Outer Mitochondrial Membrane (TOM) complex, and respectively 
through the IMM by the Translocase of the Inner Mitochondrial Membrane (TIM) 
complex. Once imported, the MTS is cleaved and chaperone proteins assist in protein 
refolding (101). 
2.1.4. Mitochondrial Biogenesis Stimuli 
Mitochondrial biogenesis is an extremely regulated process. Generally, it can occur 
in response to cellular energy deprivation as is indicated by calcium transients, an 
increase in the AMP to ATP ratio, and excess ROS production (Fig. 3). A traditional 
adaptation to exercise is increased mitochondrial content (103) and this adaptation is 
mediated by the aforementioned stress signals.  
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Figure 3. Mitochondrial biogenesis. Mitochondrial biogenesis occurs in response to 
numerous cellular signals such as energy deprivation, ROS or Ca2+. The master regulator 
of mitochondrial biogenesis, PGC-1α, coordinates the expression of nuclear genes 
encoding mitochondrial proteins (NUGEMPS), such as TFAM. Mature TFAM protein 
and other NUGEMPs can then enter the mitochondria through the protein import 
machinery (e.g. TOM and TIM complexes). These proteins increase the replication and 
transcription of mtDNA, and increase ETC capacity. Concurrently, new phospholipids 
are integrated from the endoplasmic reticulum to expand the mitochondrial membrane. 
Collectively, these processes result in an expanded mitochondrial network.  
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2.2. Mitochondrial Dynamics 
The fusion and fission of mitochondria is an intermediate regulatory loop that lies 
between biogenesis and degradation. When mitochondria are part of a network they share 
their contents and are able to maintain function. In 2001, two COX activity deficient 
cybrid lines, containing homoplasmic mtDNA for the A3243G and A4269G mutations, 
were fused using electric pulses (37, 96). The authors found that 10-14 days after fusion, 
the fused cells regained COX activity. This is evidence of “functional complementarity,” 
whereby mtDNA from different mitochondria can share their contents. OMM fusion and 
IMM fusion is mediated by the mitofusin proteins (Mfn1 and Mfn2) and Opa1, 
respectively (86). In mice deficient of Mfn1 and Mfn2, there was a loss of mtDNA 
stability and progressive loss of COX enzyme activity in skeletal muscle (37, 104). This 
emphasizes the requirement of functional, reticular organelles.  
Lastly, mitochondrial fission is the process of mitochondria budding off from the 
reticulum. The proteins, Drp1 and Fis1, regulate mitochondrial fission (86). 
Dysfunctional mitochondria undergo fission from the mitochondrial network upon loss of 
membrane potential. These punctate mitochondria can then be engulfed by 
autophagosomes and degraded, through mitochondrial autophagy. 
2.3. Mitochondrial Degradation 
The removal of dysfunctional mitochondria is critical to cellular function. 
Accumulation of oxidative damage to mitochondrial proteins, lipids and DNA can lead to 
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cellular dysfunction. Proteolytic pathways involved in mitochondrial quality control 
include innate mitochondrial proteases and the ubiquitin-proteasome degradation of 
OMM proteins. Whole organelle degradation is achieved by mitochondrial autophagy 
(mitophagy). 
2.3.1. Mitochondrial Proteases 
Mitochondrial proteins can be degraded by intrinsic proteases. These enzymes are 
important to the regulation and function of the organelle because they degrade oxidized 
proteins and facilitate targeting of mitochondria for mitophagy. For example, Lon 
protease degrades phosphorylated TFAM to regulate mtDNA copy number (104, 105) 
and preferentially degrades oxidized proteins, such as Aconitase (105, 106).  An 
important protease for organelle quality control is PARL. Under normal conditions, 
PARL cleaves PINK1 and prevents its stabilization on the OMM (106, 107). However, 
when mitochondria lose their membrane potential, PINK1 accumulates on the OMM and 
signals for the degradation of mitochondria through mitophagy (106-108). 
2.3.2. Ubiquitin-Proteasome Degradation of OMM Proteins 
The ubqiquitin-proteaseome system dismantles cytosolic proteins tagged for 
degradation by E3 ubiquitin ligases (108, 109). The proteasome is known to degrade 
proteins of the endoplasmic reticulum (ER) membrane, and recently has been identified 
to play a similar role in degrading OMM proteins (109, 110). Tanaka et al. showed that 
Mfn1 and Mfn2 are ubiquitinated and can be selectively degraded by the proteasome in a 
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p97 AAA+ protease dependent manner (110, 111). Furthermore, this was suggested to 
prevent mitochondrial fusion and enabled subsequent mitophagy to occur. 
2.3.3. Mitophagy 
Autophagy or “self-eating” is a highly conserved cellular process. Originally, 
macroautopagy (henceforth referred to as “autophagy”) was thought to be an imprecise 
degradation process. Recent literature dictates that autophagic substrates can be very 
specific. Of particular note, whole mitochondria can be processed through mitochondrial 
autophagy or mitophagy. Our understanding of the mitophagy pathway is incomplete. 
However, it has been suggested that mitophagy is essential to the health of many tissues, 
including skeletal muscle where it appears to be critical to the maintenance of muscle 
mass (111-113). 
2.3.3.1. Autophagy Induction and Autophagosome Maturation 
Mitophagy and general autophagy induction share similar pathways. The processes 
can be initiated by many disturbances, such as serum starvation, glucose starvation, 
amino acid starvation, and exercise (112-114). Mammalian Target of Rapamycin 
Complex 1 (mTORC1) and AMPK are nutrient sensitive complexes that regulate the 
autophagy initiation signal cascade. Briefly, mTORC1 activity is reduced in the absence 
of free amino acids and AMPK is activated under conditions of energy depletion by an 
increase in the AMP/ATP ratio, and other signals (reviewed in section 3.3). mTORC1 is 
a multi-protein complex, comprised of mTOR, raptor, GβL, and PRAS40. mTORC1 is 
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the major negative regulator of autophagy, that is to say, when active, mTORC1 inhibits 
the induction of autophagy. mTORC1 decreases the activity of the Ulk1-Atg13-FIP200 
complex by phosphorylating Ulk1 on Ser757 (114-116). Contrasting the role of 
mTORC1, AMPK can initiate autophagy by two mechanisms. AMPK can bind and 
phosphorylate Ulk1 at Ser317 and Ser777, thus activating the protein complex (112, 114-
116). Also, AMPK can inactivate mTORC1 by phosphorylating TSC2, a protein 
upstream of mTORC1. This alleviates the inhibition on Ulk1. Ulk1 then phosphorylates 
Atg13, FIP200 and itself, activating the complex (112, 117). An active Ulk1-Atg13-
FIP200 phosphorylates Ambra1, activating it (112, 117), and initiating the maturation of 
the autophagosome. 
The maturation of the autophagosome requires the sequestering of a lipid 
membrane and, sequentially, its elongation and maturation. The origin of the 
autophagosomal membrane is unknown (112). However, the protein complexes required 
for its maturation are well characterized. The core of PI3K Class III complex is Beclin-1, 
Vps34, and p150 (112). Its role in the creation of autophagosomal membrane is 
positively regulated by Ambra1 (activated by the Ulk1-Atg13-FIP200 complex), Atg14, 
Rab5, UVRAG, and Bif1 binding, and negatively regulated by Rubicon, IP3R, NAF-1 
and Bcl-2 binding (112). Concurrently, autophagy related genes (ATGs) covalently 
attach PE to Microtubule-Associated Light Chain 3 (LC3) to create LC3-II (112, 118), in 
a series of sequential conjugation steps. ROS, produced during starvation, is essential to 
activation of Atg4, the initial enzyme in this process (118, 119). Consequently, LC3-II 
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integrates into the autophagosomal membrane and serves as an anchor protein to attach 
the autophagosome to its target. Critical to conversion of LC3-I to LC3-II is Atg7. Atg7 
conjugates to LC3-I and serves as an intermediate prior to the attachment of PE. 
Elimination of Atg7 in reticulocytes and skeletal muscle animals yields delayed 
mitophagy initiation (119, 120) and accumulate dysmorphic and respiratory-deficient 
mitochondria (120, 121). 
2.3.3.2. Cargo Selection 
Although general autophagy and mitophagy share many mechanisms, the 
distinguishing characteristic of mitophagy is that it selectively degrades mitochondria. 
For a mitochondrion to be degraded, it must be segregated from the mitochondrial 
network, targeted, and consequently enveloped by an autophagosome. 
Segregation occurs when a fission event occurs that results in two mitochondria of 
unequal membrane potentials (106, 107, 121). The depolarized mitochondrion is 
prevented from fusing back into the mitochondrial network when PINK1 selectively 
accumulates on depolarized mitochondria (refer to section 2.3.1; 106, 107, 122). The 
ubiquitin E3 ligase, Parkin, is then attracted to the mitochondria and will ubiquitinate 
OMM proteins, such as Mfn1 and Mfn2 (110, 122). This leads to proteolytic degradation 
of Mfn1 and Mfn2 (see section 2.3.2; 110, 123), preventing the fusion of the depolarized 
mitochondrial back into the organelle network. The autophagosome is then tethered to 
other ubiquitinated OMM proteins by p62, which has binding motifs for both LC3-II and 
ubiquitin (123). This allows for the autophagosome to envelope the mitochondrion and 
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consequently shuttle it to a lysosome for fusion and degradation. Also, Parkin has been 
suggested to interact with Ambra1 and facilitate the induction of mitophagy in response 
to mitochondrial depolarization, thus providing a connection between mitochondrial 
dysfunction and mitophagy induction (123, 124). 
Nix is an OMM protein and has many roles in mitophagy. It is involved in the 
recruitment of Parkin to depolarized mitochondria (124, 125), and independently can 
induce autophagy and bind the autophagosome. Nix can dissociate the Bcl-2–Beclin1 
complex (125, 126), thus alleviating the inhibition of Beclin1 and inducing autophagy. 
Furthermore, it can directly bind LC3-II to initiate envelopment of a mitochondrion (126). 
2.3.3.3. Degradation by the Lysosome 
Upon maturation and envelopment of target complexes, the autophagosome fuses 
with the lysosome to produce an autolysosome (88, 112). Upon fusion, pH-dependent 
enzymes, such as Cathepsin-D, degrade the contents (127). To measure autophagic flux, 
fusion can be inhibited by lysosomal inhibitors, such as Bafilomycin A1 (BafA1) and 
Chloroquine (CQ). These chemicals raise the pH of the lysosome and prevent its fusion 
and/or decrease the activity of the proteolytic enzymes (128). 
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Figure 4. Mitophagy. Entire mitochondria can be degraded through a specialized form of 
autophagy, termed mitophagy. Energy deprivation and aberrant ROS signaling from 
dysfunctional organelles can activate AMPK and inhibit mTORC1 leading to the creation 
of an autophagosome by ATG proteins and the Vps34 complex. These autohagosomes 
contain LC3-II that can bind ubiquitinated outer mitochondrial membrane proteins. This 
allows the autophagosome to form around mitochondria targeted for degradation. The 
autophagosome then fuses with a lysosome and the contents are degraded and released 
back into the cell.  
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3. AMP-Activated Protein Kinase 
3.1. Structure 
AMPK is a heterotrimeric protein. The complete complex consists of a catalytic (α) 
and 2 regulatory subunits (β and γ). There are 2 isoforms of the α subunit (α1 and α2), 2 
isoforms of the β subunit (β1 and β2), and 3 isoforms of the γ subunit (γ1, γ2, and γ3; 129).  
The α subunit contains the kinase activity of the AMPK enzyme. Phosphorylation at 
Thr172 of the α subunit, by upstream kinases, increases AMPK activity 100-fold (130). 
Immediately, after the kinase domain is an Autoinhibitory Domain (AID), which when 
removed or mutated renders the α subunit constitutively active (131). The γ subunit 
contains four bindings sites for adenine nucleotides (129). Under basal conditions, 2 ATP 
molecules and 1 AMP molecule occupy two sites (130). Upon energy depletion or 
cellular stress, 2 AMP molecules and 1 ADP molecule replace these and prevent the 
dephosphorylation of the α subunit. The binding of AMP to these sites increases the 
activity of AMPK by an additional order of magnitude. 
Many of these isoforms have multiple versions due to alternative initiation or splice 
variants (129). Also, these subunits and their different isoforms are expressed in a tissue-
specific manner. Early studies identified general AMPK mRNA and protein levels to be 
highest in rat skeletal muscle versus other tissues, including the heart and liver (132). 
However, AMPK activity was much lower in skeletal muscle versus liver (132, 133). 
With respect to subunit isoform expression, northern and western blotting revealed that 
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α1 is found ubiquitously in all tissues and α2 is primarily present in the heart, liver, and 
skeletal muscle (134). Similar to the α subunits, the β1 subunit protein is located in liver, 
heart, brain, lung and testes, and the β2 subunit is expressed primarily in skeletal muscle, 
heart, brain and lung (135). Furthermore, the β1 subunit appears to be only expressed in 
the soleus (a predominantly slow-twitch muscle). Where as, the extensor digitorum 
longus (EDL; a primarily fast-twitch muscle), contains both β1 and β2 isoforms (136). 
Likewise, the γ subunits also have tissue-specific presence. With regards to mRNA 
content, γ1 mRNA is transcribed in all tissues, albeit at different levels, γ2 mRNA is 
present in all tissues except the lung, and γ3 mRNA is found almost exclusively in 
skeletal muscle (137). Furthermore, there is also a fiber-type specific distribution of γ 
subunit protein formation. The γ3 subunit is highly expressed in fast-twitch glycolytic 
muscle (e.g. white gastrocnemius), followed by fast-twitch oxidative muscle (e.g. red 
gastrocnemius), and is undetectable in slow-twitch muscle (e.g. soleus; 138, 139). 
Furthermore, throughout the differentiation of C2C12 myoblasts, there is a shift in 
AMPK subunit expression and activity (140). At Day 0 of differentiation, the α2 and γ2 
subunits were predominant. As differentiation progressed until day 7, there was a gradual 
increase in α1, β1, β2, and γ3 subunits expression, and this resulted in a greater AMPK 
activation. All of this data emphasizes the importance and highly regulated tissue- and 
fiber-type specific expression of the AMPK subunits. 
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3.2. Purpose and Role 
Fundamentally, AMPK may be considered a nutrient and energy sensing protein. It 
regulates the activation and inhibition of cellular processes depending on the energy-
status of the cell. When active, AMPK has been shown to inhibit energy-dependent 
pathways, including protein-synthesis, lipid-synthesis, and glycogen-synthesis (130). In 
contrast, active AMPK can increase energy production through glycolysis, fatty acid 
oxidation, autophagy, and mitochondrial biogenesis (130). The following paragraphs 
focus on its role in mitochondrial biogenesis and autophagy (Fig. 5). 
Since mitochondria are the site of oxidative phosphorylation and provide most of 
the energy to the cell, maintenance of mitochondrial quantity and quality is fundamental 
to proper energy homeostasis. In the absence of AMPK, mice have lower mitochondrial 
content and ambulate less (141), indicating an important role for AMPK in mitochondrial 
biogenesis. PGC-1α is the “master regulator of mitochondrial biogenesis.” AMPK has 
been shown to directly phosphorylate PGC-1α (142). This may allow PGC-1α to 
translocate to the nucleus and promote its own transcription, resulting in a transcriptional 
cascade leading to the expansion of mitochondrial reticulum (Fig. 4). AICAR has also 
been shown to cause increased binding of the USF-1 and GATA transcription factors to 
the promotor of PGC-1α and PGC-1α mRNA expression (143). Also, AMPK activation 
has been shown to act as a prerequisite for other post-translational modifications to PGC-
1α, such as deacetylation by SirT1 (144). This demonstrates the importance of AMPK to 
maintaining mitochondrial content. 
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Mitophagy is crucial to the maintenance of a functional mitochondrial pool. AMPK 
triggers upstream events that are shared between general autophagy and mitophagy. 
AMPK phosphorylates TSC2 and raptor, resulting in mTORC1 inhibition (145, 146). As 
well, AMPK can phosphorylate and activate Ulk1 (114; Fig. 4). These modifications 
result in increased autophagic induction (114). When Ulk1 or AMPK is absent, 
accumulation of dysfunctional mitochondria occurs (116). Thus, AMPK is crucial to 
maintaining a healthy and productive mitochondrial pool. 
3.3. Activation and Regulation 
The energy status or AMP/ATP ratio of the cell, directly regulates AMPK. 
However, AMPK is also susceptible to regulation by other signals through the 
phosphorylation of Thr172 of the AMPK α subunit (129). There are many known 
physiological regulators of AMPK, and additionally, pharmacological activators of 
AMPK are being discovered continuously and implemented in medical practice. 
Physiologically, changes in the AMP/ATP ratio and the activity of upstream 
kinases regulate the activity of AMPK. Adenylate kinase (AK) is an enzyme that 
converts 2 ADP molecules to 1 ATP molecule and 1 AMP molecule. Because of a high 
rate of activity, AK induces large changes in AMP levels, and thus it is logical that 
AMPK is more sensitive to AMP levels than ADP (147). Furthermore, the kinases that 
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Figure 5. AMPK regulation of mitochondrial biogenesis and mitophagy. The AMPK protein 
complex can phosphorylate PGC-1α. This facilitates the translocation of PGC-1α to the 
nucleus where it can stimulate the transcription of genes required for mitochondrial 
biogenesis. AMPK can also activate mitophagy. Phosphorylation of TSC2, Raptor, and 
ULK1 by AMPK activates mitophagy. TSC2 activates mitophagy by phosphorylating Rheb, 
which can then inhibit mTORC1. AMPK can also directly inhibit mTORC1 by 
phosphorylating Raptor. Inhibition of mTORC1 results in mitophagy induction. 
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activate AMPK at Thr172 are LKB1, CaMKK, and Tak1 (129). These enzymes are 
responsive to many stimuli. LKB1’s activity can increase in response to increased ROS 
production and Ca2+ elevation (129). CaMKK is highly sensitive to Ca2+ levels and is 
activated often in response to transient Ca2+ changes. The role of Tak1 in AMPK 
activation is still to be determined (129). These proteins and the pathways leading to their 
activation are considered the primary regulators of AMPK and its actions. 
Pharmacologically, AMPK has many activators. Metformin is an AMPK agonist 
used in the treatment of diabetes (148). Recent research shows that salicylate (the origin 
of Aspirin®) can directly activate AMPK (149). In laboratory research, AICAR is used 
as an AMPK agonist (150). AICAR is cell permeable and is phosphorylated by adenosine 
kinase to produce ZMP, an AMP analog. ZMP is then able to bind AMPK and increase 
its activation and prevent its dephosphorylation. Groups have shown that repeated 
treatment with AICAR results in increased mitochondrial biogenesis, both in cell culture 
and animal models (151, 152). A-769662, another AMPK agonist was identified recently. 
It activates AMPK through binding of the β subunit and is thought to be more specific 
than AICAR (129). Furthermore, Compound C is used experimentally as an inhibitor of 
AMPK (148). Thus, many drugs directly or indirectly activate AMPK and could prove 
vital for potential therapies relating to metabolic and other diseases. 
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Abstract 
Mitochondria are the primary site of cellular energy production. The structure and 
function of mitochondria requires both the nuclear and the maternally-inherited 
mitochondrial genome. There are multiple copies of mitochondrial DNA (mtDNA) per 
cell and each mtDNA molecule contains the required information to produce 13 essential 
electron transport chain (ETC) proteins. When mtDNA is depleted, this results in 
mitochondrial DNA depletion syndrome (MDS). This is characterized by a decrease in 
ETC activity. It particularly affects cell types that depend on oxidative phosphorylation 
for energy production, such as skeletal muscle, heart and brain. AMP-activated protein 
kinase (AMPK) is an enzyme that can initiate mitochondrial biogenesis and mitophagy. 
We hypothesized that treating cells harbouring low numbers of mtDNA with an AMPK 
activator (5-Aminoimidazole-4-carboxamide ribonucleoside; AICAR) would ameliorate 
the mitochondrial dysfunction and improve mtDNA copy number. We developed murine 
myoblasts (C2C12 cells) with low levels of mtDNA by chronic treatment with ethidium 
bromide. We treated selected clones for 24 hours with 1 mM AICAR to activate AMPK. 
AICAR treatment decreased markers of mitochondrial biogenesis, mitochondrial function 
(e.g. maximal cellular respiration), and mitochondrial degradation. Furthermore, AICAR 
increased ROS production in the most depleted cells. We conclude that the activation of 
AMPK may have increased mitochondrial retrograde signaling to trigger nuclear 
compensatory adaptations leading to changes in the cellular phenotype toward ATP 
conservation, in the presence of mitochondrial dysfunction.  
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Introduction 
Mitochondrial disorders are devastating diseases that affect cellular energy 
production and cause chronic morbidity. They originate from mutations in nuclear 
(nDNA) or mitochondrial DNA (mtDNA) genes that encode products essential for 
mitochondrial function and the maintenance of mtDNA. Because multiple copies of 
mtDNA exist and are randomly distributed during mitosis, symptoms of mitochondrial 
disease vary widely between patients and even between tissues within one patient. Hence, 
diagnosing the underlying disease is difficult and there is no cure. A partial or complete 
loss of mtDNA is termed mtDNA depletion syndrome (MDS). MDS is associated with at 
least 18% of respiratory chain deficiencies in childhood (1). Diseases from pathogenic 
mtDNA mutations have a diagnosed prevalence of 1 in 7,600 (2), but a minimum of 1 in 
200 live births harbour pathogenic mtDNA mutations (3). Treatments generally consist 
of nutritional supplementation and attending to secondary symptoms that include ataxia, 
diabetes mellitus, and exercise intolerance. In these diseases, there is an accumulation of 
dysfunctional mitochondria and, consequently, a deficit in energy production. 
Theoretically, many resolutions exist, such as: 1) increasing the amount of mitochondria 
to a level that can sustain the energy demands of the cell, despite the dysfunctional nature 
of those mitochondria, 2) increasing the functional capacity of each mitochondrion, 3) 
reducing the number of dysfunctional mitochondria, or 4) a combination of 1, 2 or 3. 
AMPK is a nutrient-sensing kinase that can phosphorylate PGC-1α (4) - the master 
regulator of mitochondrial biogenesis, and inactivate mTORC1 (5) - the major negative 
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regulator of autophagy. Thus, active AMPK both increases mitochondrial content by 
activating PGC-1α, and stimulates the degradation of malfunctioning organelles by 
inhibiting mTORC1. AMPK is triggered by metabolic stress, including exercise, but can 
also be stimulated pharmacologically by AICAR (5-Aminoimidazole-4-carboxamide 
ribonucleoside; 6, 7). Previous studies have investigated the triggering of the PGC-1α–
AMPK pathway to treat mitochondrial disease. Viscomi et al. (8) demonstrated improved 
mitochondrial content and function when breeding mice deficient in a cytochrome c 
oxidase activity (COX) assembly factor (Surf1) with PGC-1α overexpressing animals. 
They also showed an improvement in the COX deficiency of mice not expressing Surf1 
or Cox15 (another COX assembly factor) when treated with AICAR, and a similar 
improvement in mice expressing a mutant COX assembly factor (Sco2). Another group 
has identified AICAR as the most beneficial compound for improving mitochondrial 
function in cells with mutations in nuclear genes encoding electron transport chain (ETC) 
subunits (9, 10). However, no research has demonstrated the use of AICAR to increase 
mitochondrial biogenesis, induce mitophagy or improve cellular function in cells without 
sufficient amounts of mtDNA. 
The purpose of this study was to investigate the use of AMPK activation as a 
potential activator of mitophagy and therapy for treatment of mitochondrial disease. We 
hypothesized that activating AMPK would increase mitochondrial content and 
concurrently increase the quality of the mitochondrial pool by stimulating the 
degradation of dysfunctional organelles. 
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Methods 
 Cell Lines – ρ- Cell Generation: Muscle is a highly metabolic tissue that is very 
reliant on mitochondria for ATP production. Thus, muscle is particularly affected by 
mitochondrial disease. We chose to use C2C12 murine myoblasts treated with ethidium 
bromide (EtBr) as a model of mtDNA depletion. C2C12 derived ρ- cells were generated 
as previously described by our group (11). Briefly, murine myoblasts (C2C12, ATCC, 
Manassas, VA) were cultivated in DMEM medium containing 4.5 g/L glucose and 2 mM 
L-glutamine (Wisent, St-Bruno, QC, Canada), supplemented with 100 ng/mL EtBr, 50 
µg/mL uridine, 1 mM sodium pyruvate, 10% fetal bovine serum (Thermo-Scientific, 
Waltham, MA), and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). The medium 
was refreshed every day and cells were sub-cultured every 1 - 2 days for 6 weeks. Colony 
selection was performed by seeding cells at a concentration of ~4.5 cells/cm2 and 
removing individual colonies using cloning cylinders. Colonies were grown for an 
additional 3 weeks in the presence of EtBr. DNA extracts were collected to assess 
mtDNA depletion. Clones containing 34% (moderate; MOD) and 13% (LOW) of control 
mtDNA levels were stocked. A subset of cells was selected to confirm that mtDNA 
remained depleted after stocking (Fig. 1B).  
 AICAR Treatment – For each experiment, a new stock of frozen cells was used. 
Cells were seeded and allowed to adhere for 24 hours before treatment. Because EtBr 
inhibits mitochondrial RNA and DNA synthesis (12-15), one hour before treatment with 
AICAR, cells were washed 3 times with complete medium to remove EtBr. Cells were 
  58 
then either treated for 24 hours with 1 mM AICAR (Toronto Research Chemicals, 
Toronto, Ontario), or left untreated.  
mtDNA to nDNA Quantification – To assess the mtDNA to nuclear DNA 
(nDNA) ratio, genomic DNA (gDNA) was isolated using a standard kit (Mammalian 
Genomic DNA Miniprep, Sigma-Aldrich, St. Louis, MS). A spectrophotometer was used 
to quantify the amount of gDNA isolated, and 5 ng of gDNA was used as the template 
for amplification reactions. A StepONE Plus PCR System (Applied Biosystems Inc., 
Foster City, CA, USA) was used to perform quantitative PCR with SYBR® Green 
technology. Primers were optimized using serial dilutions and melting point dissociation 
curves. The following genes were amplified: the nDNA gene Pecam1 (forward primer: 
5'-ATGGAAAGCCTGCCATCATG-3', reverse primer: 5'-
TCCTTGTTGTTCAGCATCAC-3') and the mtDNA gene ND1 (forward primer: 5'-
CCTATCACCCTTGCCATCAT-3', reverse primer: 5'-
GAGGCTGTTGCTTGTGTGAC-3') as described previously (16). 
Cell Proliferation – Cells were harvested with 0.025% trypsin with EDTA 
(Invitrogen). The cell suspension was collected and the trypsin was inhibited by adding 
an equal volume of growth medium. A 15 µL aliquot was placed onto an hæmocytometer 
for counting. Values were expressed as the total amount of cells harvested over the 
original number plated. 
Enzyme Extraction and Cytochrome C Oxidase (COX) Activity – COX enzyme 
activity was measured as per Uguccioni and Hood (17). Briefly, cells were harvested, 
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lysed and the supernatant fraction collected. Enzyme extracts were combined with a 
solution of reduced equine cytochrome c and absorbance at 550 nm was monitored on a 
plate reader (Bio-Tek Synergy HT, Winooski, VT). Results were then corrected for total 
protein concentration, as assessed by the Bradford method.  
 mRNA Quantification – To assess mRNA transcript levels, total RNA was 
isolated using TRIzol® (Invitrogen) and quantified with a UV spectrophotometer 
(Ultrospec 2100 Pro; Biochrom, Cambridge, United Kingdom). Complementary DNA 
(cDNA) was created from 4 µg of total RNA with Superscript III and Oligo(dt)20 
(Invitrogen) according to the manufacturer’s instructions. Quantitative PCR was 
performed as described above. Primers were checked for C-G content and probability of 
primer-dimer formation. Final primers were as follows: Cox1 (forward primer: 5'-
CTAGCCGCAGGCATTACTAT-3', reverse primer: 5'-
TGCCCAAAGAATCAGAACAG-3'), Cox4 (forward primer: 5'-
CTCCAACGAATGGAAGACAG-3', reverse primer: 5'-
TGACAACCTTCTTAGGGAAC-3') and β2-Microglobulin (forward primer: 5'-
GGTCTTTCTGGTGCTTGTCT-3', reverse primer: 5'-TATGTTCGGCTTCCCATTCT-
3'). With the exception of Cox4 (50 ng), 5 ng of cDNA was used as a template for each 
reaction. All values were corrected for β2-Microglobulin mRNA content and analyzed 
using the ∆∆Ct method. 
 Flow Cytometric Analysis of mt∆Ψ, Mitochondrial Mass, ROS, and Lysosomal 
Mass – To measure mt∆Ψ, cells were incubated in complete growth media containing 
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100 nM tetratmethylrhodamine ethyl ester (TMRE; Invitrogen) for 45 minutes at 37ºC.  
To assess mitochondrial mass, cells were incubated with 100 nM MitoTracker Green FM 
(MTGFM; Invitrogen) for 45 minutes at 37ºC. ROS generation was measured using 
2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA; Sigma-Aldrich, St. Louis, MO). 
Cells were incubated with 100 µM H2DCFDA for 45 minutes at 37ºC. Lysosomal mass 
was evaluated by staining cells with 200 nM LysoTracker Red (LTR; Invitrogen) for 45 
minutes at 37ºC. 
Following incubation, cells were rinsed with PBS, trypsinized, and resuspended 
in complete growth media containing phenol red-free DMEM (Invitrogen). Fluorescence 
was assessed on the FL-1 channel (MTGFM and H2DCFDA), and the FL-2 channel 
(TMRE and LTR) of a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ). Unless otherwise stated, a total of at least 25,000 gated events were collected. 
Analyzed data were derived from the geometric mean fluorescence and corrected for 
autofluorescence from an unstained sample. To ascertain a measure of membrane 
potential per mitochondrion, TMRE fluorescence was corrected for mitochondrial mass 
by dividing by MTGFM fluorescence. Furthermore, mitochondria are significant sources 
of ROS (18) and thus we also corrected H2DCFDA fluorescence with MTGFM 
fluorescence. Prior to treatment, with AICAR, subsets of cells were confirmed to have 
lower mitochondrial mass (Supp. Fig. 1). 
 Protein Extraction and Western Blotting – Cells were harvested via 
trypsinization and resuspended in Passive Lysis Buffer (Promega, Madison, WI) 
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supplemented with protease and phosphatase inhibitors (10 ng/mL Leupeptin, 1 ng/mL 
Pepstatin A, 10 ng/mL Aprotinin, 1 mM DTT, 0.5 mM PMSF, 2.5 mM NaVO3, 50 mM 
NaF, and 50 mM β-Glycerolphosphate). Protein was then quantified via the Bradford 
method. 
 Following denaturation and disulfide bond reduction with SDS and β-
mercaptoethanol, equal amounts of protein were separated by size on SDS-PAGE gels. 
Protein was then transferred to a nitrocellulose membrane and stained with Ponceau S. 
Membranes were then probed with antibodies diluted in 5% skim milk in TBST buffer. 
Antibody concentrations were as follows: LC3 – 1º, 1:250 (Cell Signaling, Danvers, MA), 
Ρ-AMPK – 1º, 1:1000 (Cell Signaling) and T-AMPK 1º, 1:1000 (Cell Signaling). All 
secondary antibodies were diluted 1:1000 (Santa-Cruz Biotechnologies, Dallas, TX). 
Blots were incubated in enhanced chemiluminescence luminol (Santa-Cruz 
Biotechnologies) and exposures were collected on photographic film. 
 Oxygen Consumption – Whole-cell oxygen consumption rate (OCR) was 
assessed with a 96-well plate fluorescence assay (OxoPlates, Presens, Germany). Cells 
were inoculated 24 hours before treatment and treated with AICAR. Media was then 
replaced with complete growth media containing phenol red-free DMEM and respiration 
of each cell line was assessed in triplicate under the following treatments: 1) Vehicle 
Treatment – DMSO, 2) 1 µM Oligomycin, 3) 3 µM CCCP, and 4) 2 µM Rotenone and 
Antimycin A, as described by Nicholls et al. (19). Fluorescence was assessed every 3 
minutes for 3 hours on a fluorescence plate reader (Bio-Tek Synergy HT, Winooski, VT). 
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Rates from 60 mins to 100 mins were averaged and corrected for cell number (CyQuant 
Cell Proliferation Assay, Invitrogen). 
 Lactate Production – Conditioned media was removed from cell culture plates. 
The media was spun at 1400 RPM, the supernatant fraction collected, and flash frozen. 
Media was deproteinized using perchloric acid, diluted 1:5 and analyzed using a 
colormetric lactate assay kit (Sigma-Aldrich).  
Mitophagy Assessment – To assess autophagic flux, cells were simultaneously 
treated with 10 µM Chloroquine Diphosphate (CQ, Bioshop, Burlington, Ontario) and 
AICAR. Flux was measured by comparing the ratio of LC3-II to LC3-I protein content 
between conditions with CQ. 
To estimate mitophagy, cells were inoculated on to custom-made glass bottom 6-
well plates. Following treatment, cells were co-incubated with MTGFM and LTR (as 
described above). Media was replaced with complete growth media containing phenol 
red-free DMEM. Cells were then photographed under an inverted fluorescent microscope 
(Nikon TE2000-U, Melville, NY). For each experiment, a minimum of 20 cells from 
each condition was assessed. Discrete punctate mitochondria superimposed on individual 
lysosomes were counted and expressed as a percentage of the total number of lysosomes 
within the cell. Co-localization suggested that mitochondria were engulfed in lysosomes, 
and were undergoing mitophagy. 
 Statistical Analysis - All statistical analyses were completed with Graphpad 
Prism 5 (Graphpad, La Jolla, CA). Unless otherwise indicated, all results were analyzed 
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using a two-way ANOVA with Bonferonni post-hoc tests. Results were considered 
statistically significant when P ≤ 0.05. All graph bars are means with error bars showing 
the S.E.M. 
Results 
 mtDNA Content – EtBr treatment effectively reduced the mtDNA content of cell 
lines to 55% and 32% of control levels (Fig. 1B). We termed these cells with reduced 
mtDNA MOD and LOW, to indicate moderate and low levels of mtDNA, respectively. 
We then determined whether removing EtBr restored mtDNA levels during the 
subsequent 24 hours of treatment, with or without AICAR. We found that mtDNA levels 
were repleted back to control levels within this time frame (Fig. 1B), but that there was 
no additional increase in mtDNA with the provision of AICAR in the media (data not 
shown). 
 Cellular Proliferation – During the 48 hours following plating, cell number 
increased by 10-fold in the CON cells (Fig. 1C). In contrast, in MOD and LOW cells the 
rate of growth was attenuated, and increases of only 5- and 4-fold were observed, 
respectively. There was an overall effect of AICAR treatment, as CON, MOD and LOW 
cell proliferation rate were further reduced to increases of 9-, 3- and 2-fold, respectively. 
Thus, AICAR attenuated the growth rate of the cells. 
 AMPK Activation with mtDNA Depletion and AICAR Treatment – We sought 
to evaluate the basal activation of AMPK in MOD and LOW cell lines, along with the 
effectiveness of AICAR to stimulate AMPK. We assessed activation by measuring the  
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Figure 1. Treatment plan, mtDNA content after EtBr removal and cell yield following 
treatment. A) Cells were plated and treated as described in the methods. Treatment with 
AICAR occurred 24 hours prior to harvest, after EtBr had been removed. B) Relative 
quantities of mtDNA and nDNA were assessed. At 0 hours, MOD and LOW had less 
mtDNA than CON, but after removal of EtBr for 24 hours, mtDNA was restored to 
control levels. We observed no additional effect of AICAR.  mtDNA/nDNA was 
assessed 24 hours before treatment and 24 hours after removal of EtBr (†, P<0.01, main 
effect of time and interaction effect; α, P<0.05 vs. 0 hour control; *, P<0.05 vs. matched 
untreated; N = 3-6 different cell stocks and experiments); C) Cells were counted 
following treatment (48 hours) and divided by the number of cells inoculated at 0 hours. 
AICAR and mtDNA depletion both decreased cell proliferation rate. (†, P<0.0001 main 
effect of prior depletion and P<0.01 main effect of treatment; α, P<0.001 vs. untreated 
CON; β, P<0.001 vs. AICAR treated CON; * P<0.05 vs. matched untreated; N = 7 
experiments). Values are mean ± S.E.M. 
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levels of phosphorylated Thr172 on AMPK relative to the total amount of AMPK. 
AMPK phosphorylation was inversely related to the level of mtDNA observed during the 
depletion phase (Fig. 2). AICAR treatment caused an overall additional increase in the 
level of phosphorylated AMPK, and a concomitant augmentation in the expression of 
AMPK, except in control cells. Consequently, the ratio of phosphorylated to total AMPK 
remained unchanged (Supp. Fig. 2A and B).  
Mitochondrial Content and COX Enzyme – To elucidate any changes in 
mitochondrial content with prior mtDNA depletion and AICAR treatment, we measured 
both mitochondrial mass and COX activity. A main effect of prior mtDNA depletion on 
mitochondrial mass was evident, but post-hoc analysis revealed that this was a result of 
the significant decline produced by AICAR treatment. No significant effect of mtDNA 
depletion in untreated cells was observed (Fig. 3A). COX activity was more dramatically 
reduced with prior mtDNA depletion, by 60% and 80% in MOD and LOW cells, 
respectively (Fig. 3B). Thus, the restoration of COX enzyme activity lagged behind that 
of mtDNA during the 24-hour repletion phase. AICAR was not effective in preventing 
this decline in MOD or LOW cells (Fig. 3B). Indeed, AICAR further decreased COX 
activity in all cell lines. The use of a longer AICAR treatment time (i.e. 72 hours) did not 
result in any further increase in COX activity, even in CON cells (Supp. Fig. 3).  
 To determine the possible reasons for the decline in COX activity, we assayed 
both the mtDNA-encoded Cox1 mRNA transcript, and as well as the nuclear-encoded 
mRNA transcript Cox4. These represent subunits of the COX holoenzyme. In contrast to  
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Figure 2. Ratio of phosphorylated AMPK to total AMPK. After 24 hours there was no 
increase in the ratio of phosphorylated AMPK to total AMPK (N = 7). Values are mean ± 
S.E.M. 
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Figure 3. Measures of mitochondrial content and COX subunit mRNA transcript 
expression. A) Mitochondrial mass as assessed by MitoTracker Green FM staining and 
flow cytometry (†, P<0.001 main effect of prior depletion; β, P<0.01 vs. AICAR treated 
CON; N = 7 assays of ≥ 25,000 gated events); B) COX activity (†, P<0.0001 main effect 
of prior depletion and P<0.05 main effect of treatment; α, P<0.001 vs. untreated CON; β, 
P<0.001 vs. AICAR treated CON; N = 7 experiments); C) Cox1 mRNA levels (†, P<0.05 
main effect of treatment and P<0.001 main effect of prior depletion ; β, P<0.01 vs. 
AICAR treated CON; δ, P<0.05 vs. untreated MOD; N = 7 experiments); D) Cox4 
mRNA levels (†, P<0.01 main effect of treatment, P<0.0001 main effect of prior 
depletion, and P<0.001 interaction effect; α, P<0.001 vs. untreated CON; β, P<0.01 vs. 
AICAR treated CON; δ, P<0.001 vs. untreated MOD; * P<0.05 vs. matched untreated; N 
= 8 experiments). Values are mean ± S.E.M. 
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COX activity, Cox1 mRNA was not decreased with prior mtDNA depletion in the MOD 
cells, but was reduced by 34% in LOW cells (Fig. 3C). AICAR treatment led to further 
decreases in Cox1 mRNA, evident in MOD cells. Previously low levels of mtDNA also 
altered Cox4 mRNA levels (Fig. 3D). Paradoxically, Cox4 mRNA increased 1.8-fold in 
MOD cells, but decreased to 65% in LOW cells. Thus, the decline in COX activity 
observed in MOD cells could not be attributed to changes in Cox1 or Cox4 mRNA levels. 
Additionally, AICAR treatment did not enhance, but rather reduced Cox4 mRNA in 
MOD and LOW cells to levels below those found in control cells.  
Mitochondrial Membrane Potential and ROS Production – We determined the 
effect of prior mtDNA depletion and AICAR treatment on mitochondrial membrane 
potential using TMRE fluorescence. After correcting the measurements for mitochondrial 
mass, we found an overall reduction in membrane potential with prior mtDNA depletion, 
however this effect was only significant in AICAR treated cells (Fig. 4A). In addition, 
H2DCFDA fluorescence was used to evaluate ROS production. ROS levels were reduced 
by 61% and 76% in MOD and LOW cells (Fig. 4B). The overall effect of AICAR 
depended on the prior level of mtDNA. In CON cells, ROS production was decreased by 
AICAR. In contrast, AICAR increased ROS levels in LOW cells that had the lowest prior 
mtDNA level. 
Oxygen Consumption and Lactate Levels – ATP can be produced via 
mitochondrial and glycolytic pathways. To estimate the degree to which these pathways 
were used, along with overall mitochondrial functional capacity, we measured whole cell  
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Figure 4. Mitochondrial membrane potential and ROS production. A) Mitochondrial 
membrane potential measured using TMRE fluorescence (†, P<0.05 main effect of prior 
depletion; β, P<0.05 vs. AICAR treated CON; N = 8 measurements of ≥ 25,000 gated 
events); B) Whole-cell ROS production measured using H2DCFDA fluorescence (†, 
P<0.05 main effect of prior depletion and P<0.05 interaction effect; α, P<0.01 vs. 
untreated CON; N = 7-8 measurements of ≥ 25,000 gated events). Values are mean ± 
S.E.M. 
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respiration and culture medium lactate levels. Prior mtDNA depletion resulted in a 
progressive decline of both basal (vehicle) and maximal (CCCP) respiration in MOD and 
LOW cells, compared to control cells (Fig. 5A). AICAR treatment did not alter rates of 
respiration in either CON or LOW cells, but reduced respiration in MOD cells. We 
observed no differences in proton leak across the inner mitochondrial membrane, as 
measured by oligomycin-inhibited respiration, or in non-mitochondrial oxygen 
consumption following rotenone and antimycin A treatment (Supp. Fig. 5C and D). 
Lactate levels in the cell culture medium were low, and did not differ between CON, 
MOD, or LOW cell lines. However, lactate release increased significantly by 2-3 fold in 
the presence of AICAR, particularly in the CON and MOD cells (Fig. 5B). 
Mitophagy – To estimate the degree of mitochondrial degradation produced by 
depletion and AICAR treatment, we measured indices of mitophagy, including 
autophagic flux, lysosomal content, and the degree of mitochondrial co-localization with 
lysosomes. To quantify autophagic flux, we treated cells with CQ, which inhibits 
autophagosome-lysosome fusion, and compared the LC3-II/LC3-I ratio. AICAR 
treatment elicited an overall reduction in autophagic flux with previous mtDNA depletion, 
but this effect was not present in untreated cells (Fig. 6A). Similarly, we observed a 
global decrease (P ≤ 0.05) in lysosomal mass in MOD and LOW cells, but this main 
effect was largely a result of the significant effect produced by AICAR treatment (Fig. 
6B). To evaluate the degradation of mitochondria through the autophagic machinery, we 
measured the co-localization of mitochondria with lysosomes by using fluorescence  
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Figure 5. Oxygen consumption and media lactate levels. A) Oxygen consumption per 
1000 cells (Vehicle: †, P<0.0001 main effect of prior depletion; α, P<0.01 vs. untreated 
CON; β, P<0.001 vs. AICAR treated CON; CCCP: †, P<0.0001 main effect of prior 
depletion; α, P<0.001 vs. untreated CON; β, P<0.05 vs. AICAR treated CON; δ, P<0.05 
vs. untreated MOD; N = 8 experiments); B) Culture medium lactate content (†, P<0.0001 
main effect of treatment, P<0.001 main effect of prior depletion, and P<0.001 interaction 
effect; β, P<0.001 vs. AICAR treated CON; ε, P<0.001 vs. AICAR treated MOD; * 
P<0.01 vs. matched untreated; N = 8 experiments). Values are mean ± S.E.M. 
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Figure 6. Lysosomal content and autophagic flux. A) Autophagic flux was measured with 
CQ treatment. The ratio of LC3-II to LC3-I protein was expressed compared with 
matched cells not treated with CQ (†, P<0.01 main effect of prior depletion; β, P<0.01 vs. 
AICAR treated CON; N = 6 experiments); B) Lysosomal Mass was measured by staining 
with LysoTracker Red and flow cytometry (†, P<0.01 main effect of treatment and 
P<0.01 main effect of prior depletion; β, P<0.05 vs. AICAR treated CON; *, P<0.05 
significantly from matched untreated; N = 5-6 assays of ≥ 25,000 gated events). Values 
are mean ± S.E.M.  
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microscopy. When expressed as a percentage of the total number of lysosomes present, a 
significant overall effect of prior mitochondrial depletion on the number of mitochondria 
superimposed on lysosomes was observed (Figs. 7A and B). AICAR reduced this co-
localization suggesting that fewer mitochondria were being engulfed by lysosomes, 
implying a decrease in mitophagy. 
Discussion 
 The Effects of Prior mtDNA Depletion on Mitochondrial Composition and 
Function 
Without mtDNA, energy production through oxidative phosphorylation is 
impaired due to a lack of mtDNA-encoded products. This results in an energy deficit and 
disease. As a model of mtDNA depletion, we chronically treated cells with EtBr, a 
known inhibitor of mtDNA synthesis. Our treatment successfully depleted mtDNA. 
Remarkably, in just 24 hours after EtBr removal, mtDNA content was restored back to 
control levels, thereby illustrating the reversibility of this treatment, as well as the speed 
at which myoblasts can replete mtDNA. In addition, mitochondrial mass was decreased 
by mtDNA depletion (Supp. Fig. 1A) and was rapidly restored to levels in untreated 
control cells. However, mitochondrial function remained perturbed. Thus, our 
experimental design serves as a useful model to investigate the kinetics of changes of 
both functional and structural components of mitochondria in muscle cells. We observed 
effects of mtDNA depletion on COX activity. Following 24 hours without EtBr, COX 
activity remained decreased, despite the complete restoration of mtDNA. Cox1 mRNA, a  
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Figure 7. Mitophagy. A) Cells were stained with MitoTracker Green FM and 
LysoTracker Red. Mitochondria co-localized to lysosomes were counted and corrected 
for the total number of lysosomes per cell (†, P<0.05 main effect of prior depletion and 
main effect of treatment; N = 4-7 assessments. There were ≥ 20 cells per measurement); 
B) Representative images of cells quantified for mitophagy. White arrows indicate 
mitochondria co-localized with lysosomes. Values are mean ± S.E.M. 
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product of mtDNA, returned to control levels in MOD, but not LOW cells, while Cox4, a 
nuclear-encoded mRNA transcript encoding a subunit of the COX holoenzyme, was 
paradoxically elevated in MOD cells. If these changes in mRNA levels were reflected at 
the level of COXI and COXIV proteins, it is evident that normalization of these subunits 
cannot be a reason for the diminished level of COX holoenzyme activity in MOD cells. 
Thus, other subunits, likely involving the catalytic subunit COXII, or the mtDNA product 
COXIII, may be contributing to the reduced COX activity in MOD cells. The stark 
upregulation of the nuclear-encoded COX subunit IV in MOD cells may reflect a 
compensatory response of the nuclear genome to mtDNA depletion as described 
previously (11).  
Our data reveal that mitochondrial membrane composition was altered in cells 
with prior mtDNA depletion, illustrated by the lack of change in mitochondrial mass, 
assessed by MitoTracker Green, relative to the large decrement in COX activity. Thus, 
we also investigated whether mtDNA depletion caused concomitant decrements in 
mitochondrial function that persisted following the 24-hour mtDNA repletion phase. The 
low COX activity, in MOD and LOW cells, along with reduced basal and maximal 
cellular respiration, are indicative of dysfunctional ETC activity. However this 
dysfunction did not result in a significant decline in mitochondrial membrane potential in 
untreated cells, a measurement that reflects the proton pumping activity of the ETC. 
Mitochondrial membrane potential is the driving force for ATP synthesis. Thus, despite 
the effect of prior mtDNA depletion on COX activity and respiration, aerobic ATP 
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production was likely sufficient to support resting metabolism in these quiescent 
myoblasts. This is reflected in the lack of change in lactate levels measured in the media 
of untreated CON, MOD and LOW cells. It is unlikely that this lack of difference would 
be maintained if the cells were confronted with an increase in energy demands, such as 
contractile activity. 
Interestingly, ROS emission was reduced as a result of prior mtDNA depletion in 
MOD and LOW cells. This could be a result of a shift in the balance between ROS 
production by the ETC, and the anti-oxidant enzyme capacity of the MOD and LOW 
cells. It would be of interest to investigate whether the changes in MnSOD or GPx, 
known anti-oxidants, were components of the compensatory response to mtDNA 
depletion, as observed with Cox4 mRNA and total AMPK activity. 
Mitophagy is a process that degrades dysfunctional mitochondria with a reduced 
membrane potential. LOW and MOD cells had normal mitochondrial mass, but a 
disproportionately low COX activity, which suggests they contain dysfunctional 
mitochondria. However, this dysfunction did not result in a decrease in mitochondrial 
membrane potential. Thus, we conclude that despite the low COX activity, mitophagy is 
not activated in these cells, because they maintained a sufficient level of mitochondrial 
membrane potential.  
We observed that during mtDNA repletion, phosphorylated AMPK and total 
AMPK protein expression increased simultaneously. This suggests an increase in whole 
cell AMPK activity MOD and LOW cells. Since, an ATP deficit has previously been 
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described in ρ- cells (11, 20), the increase in AMPK gene expression and consequently 
total AMPK activity may be a compensatory response to a prolonged ATP-deficit 
experienced when MOD and LOW cells were incubated in EtBr. Furthermore, upon 
glucose starvation, AMPK can activate p53 and consequently induce cell cycle arrest 
(21). Thus, the elevated amount of activated AMPK that we observed during mtDNA 
repletion may lead to the decreased cellular proliferation in MOD and LOW cells. 
The Effect of AICAR Treatment 
Situated at an intersection between the regulation of mitochondrial biogenesis and 
mitophagy, AMPK is a critical regulator of cellular metabolism and consequently an 
attractive therapeutic target for mitochondrial diseases. Active AMPK can phosphorylate 
downstream targets leading to the generation of new organelles, and/or the degradation of 
dysfunctional organelles. Thus, stimulated AMPK signaling could resolve mitochondrial 
disorders via: 1) the stimulation of mitochondrial biogenesis, 2) an increase the quality of 
the existing mitochondrial pool by degrading dysfunctional mitochondria, or 3) a 
combination of the two. Activation of AMPK can be achieved via pharmaceutical 
activators, like AICAR. Thus, we investigated whether stimulating AMPK activity 
through AICAR administration could improve mitochondrial content and function in 
C2C12 cells previously depleted of mtDNA.  
In our experiments, AICAR treatment increased total AMPK activity and had a 
greater effect in cells previously depleted of mtDNA. Despite this, we did not observe a 
large increase in AMPK activity in control cells, or improvements in any of our 
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mitochondrial content or functional markers after 24 hours of AICAR treatment. Given 
that protein phosphorylation is a transient process, AMPK may have already been 
phosphorylated and dephosphorylated to normal levels within 24 hours in control cells, 
leading to an early ameliorative effect on mitochondrial content and function. Previous 
studies have shown that AICAR treatment increases phosphorylated AMPK in C2C12 
myoblasts as early as 6 hours (22).  Although we know that a longer, 72-hour treatment 
was not effective in further improving mitochondrial mass or COX activity in control 
cells, additional future work will be required to evaluate the benefits of shorter AICAR 
treatment times on mitochondrial function, because repeated, acute AICAR treatments 
have previously been shown to increase mitochondrial content in cultured myoblasts after 
5 days (23, 24). In contrast, in both MOD and LOW cells, AMPK activity and expression 
was increased, but the consequences was a worsened mitochondrial profile within these 
cell lines. Decreases in mitochondrial mass, COX activity, oxygen consumption, 
autophagy flux and mitophagy indices were evident. This likely contributed meaningfully 
to the reduced growth rate of the myoblasts in the presence of AICAR.  
Although we did not measure downstream targets of AMPK, the decreases in 
COX subunit mRNA transcription, oxygen consumption and cell proliferation, may be a 
result of a change in AMPK and mTOR signaling. AMPK inhibits mTOR through TSC2 
(25). This could attenuate COX activity and cellular respiration by preventing the 
transcriptional activity of the YY1–mTOR–PGC-1α transcription complex (26) and 
inhibiting mTORC1’s positive regulation of protein synthesis via 4E-BP1 and p70S6K. 
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Additionally, AMPK can activate the p53–p21 pathway (22) and this could result in 
slower cellular proliferation.  
The poor mitochondrial profile as a result of AICAR treatment may also be a 
result of defective mitochondrial clearance. We observed that AICAR reduced 
autophagic flux, lysosomal mass, and mitophagy in a manner that paralleled prior 
mtDNA depletion levels. This may be related to a possible decrease in global protein 
synthesis described above, or through a Bcl-2 dependent pathway. Previous studies have 
observed increased levels of Bcl-2 in ρ- cells (27), which is known to inhibit Beclin-1 and 
the induction of autophagy (28). Previous studies have also shown that AICAR decreases 
autophagic flux through a Beclin-1 dependent mechanism (29). Thus AICAR may 
selectively inhibit autophagy in MOD and LOW cells because of their higher Bcl-2 
content. AICAR treatment also induced a reduction of lysosomal mass and mitophagy 
indices. It is likely that the decreases in mitophagy resulting from AICAR treatment are 
secondary to decrements in autophagic flux, and to the reduction in lysosomal mass 
observed. It will also be interesting to investigate the underlying cause of these changes, 
possibly via changes in the expression of TFEB, a transcription factor which regulates 
lysosomal content (30).  
Compensatory mechanisms may be upregulated with AICAR treatment in cells 
that previously had the least amount of mtDNA. AICAR treatment ameliorated ROS 
production in control cells, but caused greater ROS production in LOW cells. This may 
be an example of mitochondrial retrograde signaling, whereby the increased ROS 
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production may initiate a cytoplasmic signal cascade to invoke a nuclear genome 
response. Evidence for a similar induction of gene expression, particularly in LOW cells 
has been shown previously (20). mtDNA depletion resulted in increased mitochondrial 
Ca2+ release and an increase in Cox5b mRNA. Furthermore, we observed that culture 
medium lactate concentration was increased with AICAR treatment in control and MOD 
cells. AICAR is known to activate glucose oxidation in muscle, via an increase in 
glucose uptake (31). Other studies have shown a decrease in basal and insulin stimulated 
glucose uptake in L6 myoblasts depleted of mtDNA, because of a decrease in GLUT4 
translocation to the plasma membrane (32).  This may explain the increased lactate levels 
in control and MOD cells, and the absence of a response in LOW cells.  
Conclusion 
Following 24 hours of EtBr removal, mtDNA content rapidly repletes in cells 
depleted of mtDNA. However, other mitochondrial markers remain attenuated, such as 
COX activity and cellular respiration. In contrast, the transcription of nuclear genes 
encoding mitochondrial proteins (NUGEMPs) such as Cox4 and other genes, may 
increase more rapidly as a compensatory response.  
AICAR treatment for 24 hours did not improve mitochondrial content and 
function in myoblasts. Treatment with AICAR attenuated ATP consuming processes, 
such as cellular proliferation, and possibly protein synthesis, along with autophagy (Fig. 
8). This may have served to induce an energy sparing mechanism within the cell to 
maintain ATP levels in the presence of declining mitochondrial function.  
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Figure 8. Summary of AICAR induced effects. In our control cells that have a functional 
mitochondrial profile, AICAR treatment for 24 hours led to increases in lactate and a 
decrease in ROS production. In contrast, MOD and LOW cells, with a compromised 
mitochondrial profile, contained more total cellular active AMPK. AICAR treatment 
resulted in a decrease in cellular respiration, an increase in ROS production, a decrease in 
mitophagy, and a reduction in cellular proliferation. 
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Future Work 
Our results demonstrate that AICAR treatment induced a mitochondrial-
preservation program in cells previously depleted of mtDNA. In our experiments, the 
underlying mechanisms responsible are thus far largely unidentified and to elucidate 
these pathways we could perform the following experiments.  
1. AICAR has been shown to have AMPK-independent effects. To reveal the role of 
AMPK in the results we observed, we should complete treatments with AMPK 
inhibitors, such as Compound C, or alternatively, transfect cells with a dominant 
negative AMPK α, or siRNA against AMPK α. We can then assess markers of 
mitochondrial content, such as COX activity or mitochondrial mass. Other 
AMPK agonists, such as A-769662, could also be employed to confirm the role of 
AMPK in our results.  
2. To confirm if AMPK activation with AICAR is indeed a transient process in our 
control cells, we should treat cells for 1, 6, 12 and 24 hours with AICAR and 
immunoblot for the phosphorylation status of AMPK. 
3. To elucidate the mechanisms responsible for our results, we could perform an 
experiment to infer the role of transcription factors, such as mTOR, TFEB, and 
p53, and determine the content and activation of anti-oxidants, autophagy 
inhibitors, protein synthesis markers and cell cycle arrest markers. Following 24 
hours of treatment with AICAR, we could perform cell subfractionation followed 
by immunoblotting of the nuclear and cytosolic fractions to determine if mTOR, 
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TFEB and p53 translocate to the nucleus. This would suggest an increase in their 
transcriptional activity. Furthermore, immunoblotting on entire cell fractions 
would elucidate the amount of anti-oxidants, such as GPx and MnSOD, the 
content of autophagy inhibitors, such as Bcl-2, the phosphorylation status of 
protein synthesis regulators and mTORC1 targets, such as 4E-BP1 and p70S6K, 
and cell cycle inhibitors and p53 transcriptional activity products, such as p21. 
These additional studies may provide a better insight into the role of AMPK in 
regulating mitochondrial content in cells with compromised mitochondrial profiles. 
  87 
Appendix A: Data and Statistical Analyses 
Table 1A. mt/nDNA ∆∆Ct values and statistical analysis before and after removal of 
EtBr 
 
  Raw Values  
 CON MOD LOW 
 0 H 48 H 0 H 48 H 0 H 48 H 
N       
1 572319 793446 358134 777998 190848 852338 
2 404478 509173 174254 655230 161595 777265 
3 654870 683923 378419 753626 123453 788614 
4  460534  700757  781851 
5  771702  676887  527535 
Mean 543889 643756 303602 712899 158632 745520 
S.E.M. 73667 67850 64939 23094 19512 56175 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.0019 Yes 
Time < 0.0001 Yes 
Depletion 0.0727 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON 0 H vs. CON 48 H P > 0.05 No 
CON 0 H vs. MOD 0 H P < 0.05 Yes 
CON 0 H vs. LOW 0 H P < 0.01 Yes 
CON 48 H vs. MOD 48 H P > 0.05 No 
CON 48 H vs. LOW 48 H P > 0.05 No 
MOD 0 H vs. MOD 48 H P < 0.001 Yes 
LOW 0 H vs. LOW 48 H P < 0.001 Yes 
MOD 0 H vs. LOW 0 H P > 0.05 No 
MOD 48 H vs. LOW 48 H P > 0.05 No 
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Table 1B. Individual values for cell proliferation and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 9.74 7.38 6.92 2.65 3.90 1.00 
2 9.91 8.94 6.79 2.62 3.97 1.94 
3 13.83 9.24 5.94 2.99 4.87 2.14 
4 5.88 6.78 6.14 2.62 4.39 2.56 
5 11.18 12.29 4.00 2.13 4.26 3.17 
6 17.61 9.98 4.52 3.17 3.76 2.68 
7 5.54 5.54 3.75 2.58 4.04 2.17 
Mean 10.53 8.59 5.44 2.68 4.17 2.24 
S.E.M. 1.61 0.85 0.50 0.13 0.14 0.26 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.8311 No 
Depletion < 0.0001 Yes 
Treatment 0.0014 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P < 0.001 Yes 
CON UT vs. LOW UT P < 0.001 Yes 
CON AICAR vs. MOD AICAR P < 0.001 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P < 0.05 Yes 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 2A. Individual values of phosphorylated AMPK protein levels and statistical 
analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 1.359 1.569 2.132 5.457 2.883 10.684 
2 0.000 1.814 1.323 2.682 1.606 1.194 
3 0.000 2.049 1.077 1.628 2.592 5.288 
4 3.432 6.090 1.795 0.431 2.656 3.060 
5 2.761 0.349 2.865 6.287 3.542 3.018 
6 1.439 1.730 1.812 4.497 2.728 2.916 
7 1.489 1.648 0.353 3.425 4.019 7.862 
Mean 1.497 2.178 1.623 3.487 2.861 4.860 
S.E.M. 0.484 0.684 0.303 0.790 0.289 1.263 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.6052 No 
Depletion 0.0140 Yes 
Treatment 0.0254 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.05 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 2B. Individual values of total AMPK protein levels and statistical analysis 
 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 1.375 1.283 1.449 3.061 1.969 4.411 
2 0.000 1.240 1.473 1.948 2.545 3.833 
3 1.875 2.195 2.128 5.407 3.104 6.568 
4 1.220 1.505 1.803 2.975 3.373 4.335 
5 2.204 1.440 2.259 2.401 2.833 3.240 
6 0.459 0.721 0.876 0.286 1.321 1.901 
7 2.207 2.065 2.582 3.850 3.799 6.083 
Mean 1.334 1.493 1.796 2.847 2.706 4.339 
S.E.M. 0.323 0.191 0.219 0.601 0.320 0.606 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.2117 No 
Depletion < 0.0001 Yes 
Treatment 0.0079 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P < 0.05 Yes 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P < 0.05 Yes 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P < 0.05 Yes 
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Table 3A. Mitochondrial mass values and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 74.17 102.30 72.52 84.18 86.62 65.47 
2 184.93 208.33 147.79 122.89 102.88 81.32 
3 88.93 126.83 97.50 87.59 90.66 45.65 
4 112.42 118.69 96.14 118.07 62.44 52.91 
5 142.07 152.99 81.67 84.34 57.39 59.86 
6 40.12 104.81 40.46 79.19 30.99 67.40 
7 161.10 164.15 181.26 49.21 146.75 91.61 
8 140.37 194.12 115.71 106.92 112.72 100.15 
9 133.38 176.54 118.78 132.69 117.06 94.93 
Mean 119.72 149.86 105.76 96.12 89.72 73.26 
S.E.M. 15.13 12.96 13.87 8.74 11.76 6.50 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.1168 No 
Depletion 0.0002 Yes 
Treatment 0.8903 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P < 0.01 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 3B. Raw COX activity values and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 362.18 175.58 110.62 63.21 37.91 4.77 
2 506.11 399.27 273.95 165.39 55.43 24.38 
3 480.45 248.79 78.81 59.05 1.22  
4 364.02 465.60 177.36 70.57 168.80 83.21 
5 369.74 369.58 196.54 130.72 40.79 55.47 
Mean 416.50 331.76 167.46 97.79 60.83 41.96 
S.E.M. 31.63 52.53 34.19 21.32 28.43 17.26 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.6140 No 
Depletion < 0.0001 Yes 
Treatment 0.0486 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P < 0.001 Yes 
CON UT vs. LOW UT P < 0.001 Yes 
CON AICAR vs. MOD AICAR P < 0.001 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 3C. Raw ∆∆Ct values of COXI mRNA levels and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 19817.77 21945.77 11545.79 13798.75 13186.33 5039.82 
2 19980.02 20555.92 15441.28 14333.85 9951.28 3653.42 
3 14893.99 17230.35 15712.33 15828.77 13937.95 6813.12 
4 23085.77 22838.37 48175.59 12379.88 18329.68 12919.82 
5 24282.52 26847.25 20460.31 16498.00 9931.28 5412.00 
6 19969.93 18825.46 22888.79 13086.39 8217.50 9061.36 
7 14618.58 8082.69 13174.16 9373.10 13508.00 5245.87 
Mean 19521.22 19475.12 21056.89 13614.11 12437.43 6877.92 
S.E.M. 1391.50 2226.36 4760.54 893.92 1281.25 1193.88 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.2781 No 
Depletion 0.0005 Yes 
Treatment 0.0302 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.01 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P < 0.05 Yes 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 3D. Raw ∆∆Ct values for COXIV mRNA levels and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 2.343 4.514 3.815 4.047 3.164 0.286 
2 2.674 4.417 5.610 1.176 2.201 1.217 
3 4.467 3.699 2.937 1.456 2.061 0.506 
4 3.247 4.512 7.038 1.449 1.158 0.788 
5 3.187 2.837 5.476 0.604 1.695 0.511 
6 3.661 4.417 12.933 3.077 1.577 0.646 
7 2.634 3.150 4.269 1.486 1.749 0.487 
8 2.750 5.107 2.892 1.961 1.571 0.383 
Mean 3.120 4.081 5.621 1.907 1.897 0.603 
S.E.M. 0.243 0.274 1.159 0.396 0.213 0.103 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.0003 Yes 
Depletion < 0.0001 Yes 
Treatment 0.0033 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P < 0.01 Yes 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P < 0.05 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P < 0.001 Yes 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P < 0.001 Yes 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 4A. Individual values for mitochondrial membrane potential after correction for 
mitochondrial mass and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 0.837 0.741 0.625 0.611 0.335 0.254 
2 0.293 0.407 0.223 0.232 0.292 0.212 
3 0.459 0.515 0.387 0.366 0.409 0.221 
4 0.945 0.914 0.388 0.415 0.765 0.663 
5 0.675 0.664 0.468 0.495 0.762 0.794 
6 0.342 0.403     
7 0.538 0.620 0.287 0.359 0.271 0.149 
8 0.424 0.496 0.272 0.351 0.320 0.153 
Mean 0.564 0.595 0.379 0.404 0.450 0.350 
S.E.M. 0.083 0.062 0.052 0.046 0.082 0.100 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.6079 No 
Depletion 0.0201 Yes 
Treatment 0.8075 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.05 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 4B. Individual values for reactive oxygen species after correcting for 
mitochondrial mass and statistical analysis 
 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 0.026 0.007 0.004 0.012 0.014 0.036 
2 0.054 0.035 0.015 0.018 0.014 0.034 
3 0.036 0.028 0.011 0.018 0.019 0.015 
4 0.075 0.044 0.021  0.052 0.062 
5 0.032 0.022 0.015 0.02 0.021 0.019 
6 0.020 0.017     
7 0.053 0.018 0.029 0.021 0.021 0.028 
8 0.011 0.006 0.009 0.011 0.010 0.042 
Mean 0.038 0.022 0.015 0.017 0.022 0.034 
S.E.M. 0.007 0.005 0.003 0.002 0.005 0.006 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.0299 Yes 
Depletion 0.0253 Yes 
Treatment 0.8684 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P > 0.05 No 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 5A-I. Raw oxygen consumption values after vehicle treatment and statistical 
analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 28.04 23.67 33.73 8.94 14.95 7.47 
2 59.06 82.83 74.48 13.35 31.98 17.43 
3 54.60 69.27 26.00 11.86 19.33 11.51 
4 59.06 25.89 13.5 13.84 16.37 11.08 
5 57.84 75.96 18.21 23.27 21.60 25.63 
6 30.66 33.60 26.48 13.85 7.58 8.34 
7 34.69 42.54 41.38 17.73 11.17 9.24 
8 26.13 19.22 16.35 19.97 9.73 25.43 
Mean 43.76 46.62 31.27 15.35 16.59 14.52 
S.E.M. 5.34 9.04 6.99 1.64 2.77 2.63 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.2118 No 
Depletion < 0.0001 Yes 
Treatment 0.2612 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P < 0.01 Yes 
CON AICAR vs. MOD AICAR P < 0.001 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 5A-II. Raw oxygen consumption values after CCCP treatment and statistical 
analysis 
 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 31.47 23.20 20.55 14.96 8.21 7.56 
2 156.45 99.33 92.86 40.82 19.48 12.79 
3 172.42 121.49 94.86 65.75 30.18 14.24 
4 58.79 65.69 48.06 47.21 14.58 16.28 
5 112.53 141.41 69.73 47.51 21.48 47.79 
6 40.22 44.31 46.14 22.74 14.59 7.39 
7 45.08 48.66 55.41 37.22 22.74 17.10 
8 65.53 81.72 47.34 33.39 19.48 16.62 
Mean 85.31 78.23 59.37 38.70 18.84 17.47 
S.E.M. 19.38 14.35 8.92 5.57 2.32 4.54 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.6660 No 
Depletion < 0.0001 Yes 
Treatment 0.2833 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P < 0.001 Yes 
CON AICAR vs. MOD AICAR P > 0.05 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P < 0.05 Yes 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 5B. Individual lactate concentration values and statistical analysis 
 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 19.05 90.75 27.31 114.36 30.85 43.84 
2 22.29 118.49 70.39 145.64 22.59 36.75 
3 60.66 182.82 61.25 60.95 23.47 40.59 
4 73.64 199.64 26.13 66.85 28.20 34.10 
5 32.03 83.08 19.05 147.41 30.26 56.82 
6 41.50 134.01 61.09 63.27 76.60 99.18 
7 40.96 169.11 33.34 92.11 82.86 66.81 
8 44.77 125.03 38.24 48.31 50.21 47.49 
Mean 41.86 137.87 42.10 92.36 43.13 53.20 
S.E.M. 6.51 14.99 6.85 13.87 8.55 7.59 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.0007 Yes 
Depletion 0.0010 Yes 
Treatment < 0.0001 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.001 Yes 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P < 0.01 Yes 
CON AICAR vs. LOW AICAR P < 0.001 Yes 
MOD UT vs. MOD AICAR P < 0.01 Yes 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P < 0.05 Yes 
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Table 6A. Ratio of LC3-II to LC3-I protein and statistical analysis 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 1.110 0.963 0.750 0.773 0.893 0.233 
2 0.557 0.435 0.253 0.000 0.109 0.000 
3 0.638 0.622 0.569 0.438 0.380 0.355 
4 0.579 0.574 0.378 0.774 0.437 0.048 
5 1.183 0.739 0.635 0.479 -0.060 -0.210 
6 0.378 1.247 1.232 0.067 0.937 0.440 
Mean 0.741 0.763 0.636 0.422 0.449 0.144 
S.E.M. 0.133 0.121 0.14 0.136 0.165 0.099 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.4591 No 
Depletion 0.0075 Yes 
Treatment 0.1400 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.01 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 6B. Raw values of lysosomal mass and statistical analysis. 
 
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 21.12 20.38 18.07 10.69 27.20 13.71 
2 33.30 27.80 26.11 15.58 23.93 14.41 
3 36.18 24.89 20.31 14.40 11.15 8.26 
4 31.66 22.98  27.12 27.34 13.13 
5 26.06 21.32 26.66 17.37 22.03 10.86 
6 16.22 13.42 15.91 13.58 11.77 3.56 
Mean 27.42 21.80 21.41 16.46 20.57 10.66 
S.E.M. 3.14 2.00 2.15 2.32 3.00 1.69 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.5548 No 
Depletion 0.0033 Yes 
Treatment 0.0020 Yes 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P < 0.01 Yes 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 Yes 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Table 7. Percentages of lysosomes co-localized with mitochondria and statistical analysis  
  Raw Values  
 CON MOD LOW 
 Untreated AICAR Untreated AICAR Untreated AICAR 
N       
1 65.51 58.16 67.25 45.40 48.35 35.22 
2 104.08 62.72 72.80 50.36 55.70 53.75 
3 89.75 96.72     
4    14.11 48.83 15.93 
5     66.85  
6 27.89 31.51 13.93 9.74 28.32 15.27 
7 45.73 38.40 42.19 18.74 31.75 11.54 
Mean 66.59 57.50 49.04 27.67 46.63 26.34 
S.E.M. 13.92 11.42 13.47 8.41 5.93 8.00 
 
2-Way ANOVA 
 P-Value Significant 
Interaction 0.8034 No 
Depletion 0.0331 Yes 
Treatment 0.0543 No 
 
Bonferroni Post-Hoc Tests 
Cell Line Treatment  Cell Line Treatment P-Value Significant 
CON UT vs. CON AICAR P > 0.05 No 
CON UT vs. MOD UT P > 0.05 No 
CON UT vs. LOW UT P > 0.05 No 
CON AICAR vs. MOD AICAR P > 0.05 No 
CON AICAR vs. LOW AICAR P > 0.05 No 
MOD UT vs. MOD AICAR P > 0.05 No 
LOW UT vs. LOW AICAR P > 0.05 No 
MOD UT vs. LOW UT P > 0.05 No 
MOD AICAR vs. LOW AICAR P > 0.05 No 
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Appendix B: Additional Data 
A 
 
B 
 
C 
  
D 
 
Supplementary Figure 1. Pre-treatment mitochondrial content and quality, and 
lysosomal content. Mitochondrial mass (A), membrane potential (B), reactive oxygen 
species (C), and lysosomal mass (D) were measured on a flow cytometry (1-way 
ANOVA;  † indicates significant main effect of prior depletion P<0.05; * indicates vs. 
control; N = 3 measurements of ≥ 10,000 gated events). 
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Supplementary Figure 2. AMPK phosphorylation and expression after AICAR 
treatment. A) P-AMPK protein levels relative to Ponceau S staining (†, P<0.05 main 
effect of prior depletion and treatment; β, P<0.05 vs. AICAR CON; N=7 experiments); 
B) T-AMPK protein levels relative to Ponceau S staining (†, P<0.0001 main effect of 
treatment and P<0.01 main effect of prior depletion; α, P<0.05 vs. untreated CON; β, 
P<0.001 vs. AICAR treated CON; ε, P<0.05 vs. AICAR treated MOD; * P<0.05 vs. 
matched untreated; N = 7 experiments). Values are mean ± S.E.M. 
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Supplementary Figure 3. Mitochondrial mass and COX activity. After 72 hours, 
mitochondrial mass and mitochondrial content were not significantly increased with 
AICAR treatment in control cells (N = 4). 
  
Un
tre
ate
d
72
H 
AI
CA
R
0
50
100
150
200
M
ito
ch
on
dr
ia
l M
as
s (
A
. U
.)
Un
tre
ate
d
72
H 
AI
CA
R
0
200
400
600
C
O
X
 A
ct
iv
ity
(m
U
/μg
 o
f P
ro
te
in
)
  106 
A 
 
B 
 
Supplementary Figure 4. Uncorrected values for mitochondrial membrane potential 
and reactive oxygen species. A) An overall main effect of prior depletion was observed 
for reactive oxygen species generation (†, P<0.05 main effect of prior depletion; α, 
P<0.05 vs. untreated CON; N = 7-8); B) There was an overall decrease in mitochondrial 
membrane potential (†, P<0.05 effect of interaction and P<0.05 main effect of prior 
depletion; α, P<0.001 vs. untreated CON; β, P<0.001, vs. AICAR treated CON; ε, P<0.05 
vs. AICAR treated MOD; *, P<0.05 vs. matched untreated; N = 7-8).  
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Supplementary Figure 5. Respiration in growth media or growth media containing the 
vehicle (DMSO) for respiration reagents. Oligomycin, CCCP, rotenone and antimycin A 
are dissolved in DMSO. We found that respiration decreases with mtDNA depletion and 
respiration is slightly increased with DMSO treatment. Furthermore, we found no defects 
in mitochondrial membrane leak or non-mitochondrial oxygen consumption. A) 
Respiration in growth media (†, P<0.05 main effect of prior depletion; α, P<0.05 vs. 
untreated CON; β, P<0.05, vs. AICAR treated; N = 8 experiments) B) Respiration in 
cells treated with vehicle (†, P<0.05 main effect of prior depletion; α, P<0.05 vs. 
untreated CON; β, P<0.05, vs. AICAR treated; N = 8 experiments). C) Respiration cells 
treated with oligomycin. D) Respiration in cells treated with rotenone and antimycin A.
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Appendix C: Laboratory Methods and Protocols 
C2C12 ρ- Generation  
Reagents: 
• 100 ng/mL Ethidium bromide (EtBr) 
• Complete Growth Medium 
o DMEM 
 4.5 g/L Glucose 
 With Glutamine 
o 1 mM Sodium Pyruvate 
o 50 µg/mL Uridine 
• Cloning Cylinders 
• Autoclaved Vacuum Grease in a glass 60 cm2 petri dish 
• DPBS 
• Trypsin 
Procedure: 
1. Obtain a low passage of C2C12 cells. 
2. Stock a minimum of 2 cryovials for the generation of ρ- cells and passage-
matched controls. 
3. Start growing 1 cryovial in Complete Growth Medium with 100 ng/mL EtBr. 
Add EtBr fresh each time because it is light sensitive. 
4. Refresh medium every day and split cells 1:3 as necessary (typically every 2-3 
days). 
5. After a few weeks of growth start the second vial and growth in the presence 
of just Complete Growth Medium. Passage these as necessary 1:3 and change 
medium daily. These cells will serve as the passage matched controls. They 
are started later because they replicate at a faster rate than ρ- cells. 
6. After 6-weeks of growth in the presence of EtBr, seed 100 cells on 60 cm2 
tissue culture treated dishes. Seed a few plates to ensure success.  
7. After 1-3 days, use Cloning Cylinders to isolate colonies. 
a. Remove growth medium and secure the lid of the dish with tape. 
b. Invert the dish and place under inverted light microscope. 
c. With an alcohol resistant marker circle groups of cells. 
d. Wash plate with DPBS. 
e. Dip the cloning cylinders by into the petri dish of vacuum grease, to 
evenly coat the rim of the cylinders. 
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f. Place the cylinders firmly over the circled colonies. 
g. Add 200 – 500 µL of Trypsin to the middle of the cylinders and 
incubate at 37ºC for 5 minutes. 
h. Remove trypsin and place into wells of a 96-well plate. 
i. Allow colonies to grow and transfer to a 24-well plate, 25 cm2 flask, 
and 175 cm2 flask as necessary. 
j. Stock colonies and freeze aliquot as described for genomic DNA 
isolation. 
k. Isolate gDNA and perform qPCR to assess mtDNA to nDNA ratio. 
Name colonies respectively and stock desired colonies for future 
experiments. From start to finish cells are maintained in EtBr for 10.5 
weeks. 
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Cytochrome C Oxidase (COX) Activity Assay 
Part A: Enzyme Extraction  
Reagents: 
• Dulbecco’s Phosphate Buffered Saline (DPBS) 
Procedure: 
1. Grow cells up 175 cm2 flask. 
2. Pour off the medium. Wash each plate with 5 ml Dulbecco’s Phosphate 
Buffered Saline (DPBS) without Ca2+ and Mg2+. Remove all of the DPBS. 
3. Add 5 ml of Trypsin with EDTA and incubate at 37C for 5 minutes. 
4. Tap flask and inhibit trypsin with 5 mL of complete media. 
5. Spin the cells at 1400 RPM for 3 minutes. Remove all supernate. Resuspend 
in 2 mLs DPBS. Count cells and aliquot 2 x 106 cells for enzyme extraction. 
6. Spin the cells at for 3 min at 1400 RPM in a microcentrifuge. Discard the 
supernate with a Pasteur pipette. 
7. Add 150 µl enzyme extraction buffer and vortex vigorously to disperse the 
pellet. 
8. Vortex and flash freeze. Store at -80 until ready. 
9. Freeze in liq N2 and thaw at 37 oC. Vortex vigorously for 5 sec. 
10. Repeat step 9 three times. 
11. Sonicate 3 x 3 sec on ice. Make sure that the sonicator is set to 30. 
12. Spin in microcentrifuge at 4 oC for 5 min at 13.0 rcf. 
13. Remove the supernate and add it to a new, labelled eppendorf tube. 
14. Run COX activity below. Use 25 uL of sample 75 uL of test solution. Perform 
4 times. 
15. Measure the total protein concentration using a Bradford protein assay. 
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Part B: Cytochrome C Oxidase (COX) Assay with Microplate Reader 
Theory: 
Cell extract containing cytochrome c oxidase is added to the test solution 
containing fully reduced cytochrome c. The rate of cytochrome c oxidation is measured 
over time as a reduction in absorbance at 550 nm. The reaction is carried out at 30o C.  
 
Reagents: 
• Horse Heart Cytochrome c (Sigma C-2506) 
• Sodium Dithionite 
• 100mM K-Phosphate Buffer (KPO4 pH 7.0) 
• Make and mix equal proportions of 0.1M KH2PO4 and 0.1M K2HPO4.3H20 
• 10mM K-Phosphate Buffer (KPO4) 
• Dilute 100mM K-Phosphate Buffer 1:10 with ddH20 
Procedure: 
1. Immediately following the completion of the enzyme extraction protocol from 
cells proceed to making Test Solution. Add the following to a scintillation 
vial: 
a. Weigh out 10mg of horse heart cytochrome c; 
b. Add 500 uL of 10mM KPO4 buffer and fully dissolve cytochrome c. 
2. Make up a small volume of 10mg/ml sodium dithionite-10mM KPO4 stock 
solution (make fresh each experiment for immediate use within 20mins). 
3. Add 20µl of dithionite solution to the Test Solution and observe a colour 
change from red to orange. 
4. Add 4ml of ddH20. 
5. Add 500 uL of 100mM KPO4 buffer and wrap vial in aluminium foil as Test 
Solution becomes light sensitive at this step.  
6. Add ≥ 300µl of Test Solution into 7 wells of a 96-well microplate and 
incubate at 30°C for 10 minutes to stabilize the temperature of absorbance. 
7. Open KC4 plate reader program.  Select CONTROL icon, then PRE-
HEATING tab, enter 30°C and select ON.  (Do not run assay until KC4 
temperature has reached 30°C.) 
8. Setup COX activity protocol on the KC4 program. 
a. Select WIZARD icon, then READING PARAMETERS icon. 
i. Select Kinetic for Reading Type. 
ii. Select Absorbance for Reader and 550nm for wavelength 
(drop-down menu). 
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iii. Select Sweep for Read Mode. 
iv. Select 96 Well Plate (default) for Plate Type. 
v. Enter A1 – A7 
vi. Select Yes and Pre-heating and enter 30 for Temperature 
Control. 
vii. For Shaking enter 4 for intensity and 1 sec for duration. 
viii. Do not select either of the two options for Pre-reading. 
ix. Click on the KINETIC… rectangular tile to open the Kinetic 
window. 
x. Enter run time (1 minute is recommended) and select 
MINIMUM for Interval time (under these conditions the 
minimum Interval time should be 3 seconds). 
xi. Select Allow Well Zoom During Read to see data in real time 
(optional). 
xii. Under Scales, checkmarks should appear for both Auto check 
boxes.  Do not select Individual Well Auto Scaling. 
xiii. Press OK to return to Reading Parameters window.  Press OK 
to return to Wizard window.  Press OK.  Do not save the 
protocol. 
9. Set the multipipette to 75 µl and secure 7 tips on the white projections (make 
sure they are on tight and all at the same height). 
10. In a clean 96 well plate, pipette 25 µL of enzyme extraction buffer into A1 
and 25 µL of samples into the next 6 empty wells (start with A1). At all times, 
minimize the formation of bubbles. 
11. Confirm the microplate reader has reached the desired 30ºC. 
12. Remove the microplate with Test Solution from the incubator. Place this plate 
beside the plate with the sample extracts in it. 
13. Using the multipipette transfer 75 µL of test solution to the wells containing 
the relevant samples. Make sure the volume is equal in all the pipette tips and 
gently remove the multipipette tips prior to the final expulsion to minimize 
the formation of bubbles. 
14. Immediately, begin reading the plate using the microplate reader.  
15. Generate a report with an overlay of the “Well-Zoom” for each relevant well. 
On this report a delta absorbance will be given. 
16. The delta absorbance will appear in units of mOD/min and the number given 
will be negative. Convert this to OD/min by dividing by 1000 and omit the 
negative sign in the calculation. (eg. if Mean V: -394.8 mOD/min, then use 
0.395 OD/min) 
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Calculation: 
 
Example Calculation: 
Sample Volume 25 µL 
Test Solution Volume 75 µL 
Mean Delta Absorbance 0.5843 OD/min 
Sample Protein Concentration 3.2023 µg/µL 
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DNA and RNA Assessment Procedure 
Part A: Genomic DNA Isolation 
Reagents: 
• Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich G1N70) 
o Resuspension Solution 
o RNase A Solution 
o 20 mg/mL Proteinase K Solution 
o Lysis Solution C 
o Column Preparation Solution 
o Wash Solution 
o Elution Solution 
• 100% Ethanol (EtOH) 
• DEPC ddH2O 
• Complete Growth Medium 
o DMEM 
 With Glutamine 
 With 1 mM Sodium Pyruvate 
 With 50 µg/mL Uridine 
o 10% FBS 
o 1% Penicillin – Streptomycin 
• DPBS without Ca2+ or Mg2+ 
Procedure: 
1. Cell Culture: 
a. Grow cells up 175 cm2 flask. 
b. Pour off the medium. Wash each plate with 5 ml Dulbecco’s. 
Phosphate Buffered Saline (DPBS) without Ca2+ and Mg2+. Remove 
all of the DPBS. 
c. Add 5 ml of Trypsin with EDTA and incubate at 37ºC for 5 minutes. 
d. Tap flask and inhibit trypsin with 5 mL of Complete Growth Media. 
e. Spin the cells at 1400 RPM for 3 minutes. Remove all supernate. 
Resuspend in 2 mLs DPBS. Count cells and aliquot 2 x 106 cells for 
DNA extraction. 
f. Spin the cells at for 3 min at 1400 RPM in a microcentrifuge. Discard 
the supernate with a Pasteur pipette. 
g. Flash freeze and store at -80 until ready to continue 
2. DNA Isolation 
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a. Follow the directions of the Mammalian Genomic DNA Miniprep Kit 
as briefly described below. 
b. Allow pellet to thaw slightly and then resuspend the pellet in 200 µL 
of Resuspension Solution. 
c. Treat cell suspension with 20 µL of RNAse A Solution for 2 minutes 
at room temperature. 
d. Add 20 µL of 20 mg/mL Proteinase K and 200 µL of Lysis Solution C. 
Vortex vigorously and incubate at 70ºC for 10 minutes. 
e. Prepare Binding Columns 
i. Add 500 µL of Column Preparation Solution. 
ii. Centrifuge at 12000 g for 1 minute. 
f. Add 200 µL of EtOH to sample lysates and vortex vigorously. 
g. Load lysate into Binding Columns and centrifuge at 6500 g for 1 
minute. 
h. Empty collection tube and add 500 µL of Wash Solution. Centrifuge 
for 1 minute at 6500 g 
i. Empty collection tube and add 500 µL of Wash Solution. Centrifuge 
for 3 minutes at 16000 g. 
j. Replace collection tube and add 200 µL of Elution Solution for 5 
minutes. 
k. Centrifuge for 1 minute at 6500 g and store at -20ºC. 
3. Quantify DNA 
a. Use a spectrophotometer to measure the absorbance at 260 nm. 
Part B: Total RNA Isolation 
Reagents: 
• TRIZol® Reagent 
• 24:1 Chloroform:Isoamylalcohol 
o 24 parts Chlorofom 
o 1 part Isoamylalcohol 
• 100% Isopropanol 
• 75% Ethanol 
• DEPC ddH2O 
Procedure: 
1. Cell Culture: 
a. Grow cells up 175 cm2 flask. 
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b. Pour off the medium. Wash each plate with 5 ml Dulbecco’s. 
Phosphate Buffered Saline (DPBS) without Ca2+ and Mg2+. Remove 
all of the DPBS. 
c. Add 5 ml of Trypsin with EDTA and incubate at 37ºC for 5 minutes. 
d. Tap flask and inhibit trypsin with 5 mL of Complete Growth Media. 
e. Spin the cells at 1400 RPM for 3 minutes. Remove all supernate. 
Resuspend in 2 mLs DPBS. 
f. Spin the cells at for 3 min at 1400 RPM in a microcentrifuge. Discard 
the supernate with a Pasteur pipette. 
g. Flash freeze and store at -80 until ready to continue 
2. RNA Isolation 
a. Thaw pellet slightly and add 1ml TRIZOL.  Vortex thoroughly until 
pellet is completely disrupted. 
b. Add 200 µL of 24:1 chloroform:isoamlyalcohol. 
c. Shake vigorously for 15 seconds and leave @ room temperature for 5 
minutes. 
d. Spin at 14000 g for 15 minutes at 4oC. 
e. Transfer the upper phase carefully to a new eppendorf tube.  Add 500 
µL of 100% isopropanol and briefly shake. 
f. Incubate at room temperature for 30 minutes. 
g. Spin at 14000 g for 10 minutes at 4oC. 
h. Remove supernatant. Add 500 µL of 75% EtOH and wash the RNA 
pellet with gentle pipetting. 
i. Spin at 14000 g for 1 minute at 4oC. 
j. Carefully, remove supernatant and air dry the RNA pellet. 
k. Resuspend the pellet in 50 µL of DEPC ddH2O. 
l. Heat RNA samples at 65oC for 10 minutes. 
3. Quantify RNA 
a. Use a spectrophotometer to measure the absorbance at 260 nm. 
b. Freeze and store at -80oC. 
Part C: Reverse Transcriptase 
Reagents: 
• Oligo(dt) 20 
• 10 mM dNTP 
o asd 
• DEPC ddH2O 
• Master Mix (per sample) 
o 8 µL of 5x Buffer 
o 2 µL of 0.1 M Dithiothreitol (DTT) 
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o 2 µL of RNAse Out 
• Superscript III 
Procedure: 
1. Combine 2 µL of Oligo(dt) 20, 2 µL of 10 mM dNTP, and 4 µg of Sample 
RNA in a sterile 0.5 mL sterile eppendorf. Bring the volume to 26 µL with 
DEPC ddH2O. 
2. Heat the eppendorf at 65ºC for 5 minutes, followed by 1 minute at 4ºC in a 
thermocycler. 
3. Make the Master Mix. 
4. After the eppendorfs have been heated, add 12 µL of the Master Mix and 2 µL 
of Supercript III RT. 
5. Incubate the eppendorf for 50 minutes at 55ºC, followed by 15 minutes at 
70ºC. 
6. Store samples at -20ºC. 
Part D: Quantitative Polymerase Chain Reaction (qPCR) Procedure  
Reagents: 
• DEPC ddtH2O 
• Master Mix (per sample and per gene of interest) 
o Table 1 (COX I, β2-Microglobulin, ND1 and Pecam1): 
 12.5 µL of PerfeCTa® SYBR® Green SuperMix with ROX™  
 2.5 µL of 20 µM Forward Primer 
 2.5 µL of 20 µM Reverse Primer 
 5.5 µL of DEPC ddH2O 
o Table 2 (COX IV) 
 12.5 µL of PerfeCTa® SYBR® Green SuperMix with ROX™  
 0.625 µL of 20 µM Forward Primer 
 0.625 µL of 20 µM Reverse Primer 
 9.25 µL of DEPC ddH2O 
Procedure: 
1. Biochemical Assay 
a. Autoclave qPCR microtube strips and pipette tips. Sterilize pipettes 
with EtOH for use. 
b. Dilute gDNA or cDNA Samples appropriately with DEPC ddH2O for 
the gene of interest: 
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i. cDNA for COXI and β2-Microglobulin assessments are diluted 
1:40 to obtain a 2.5 ng/µL stock. 
ii. gDNA is diluted to a 50 ng/µL stock and then 1:20 to obtain a 
2.5 ng/µL stock. 
iii. cDNA for COXIV assessment is diluted 1:4 to obtain a 25 
ng/µL stock. 
c. Create appropriate Master Mixes as determined during optimization. 
Always use a housekeeping gene to correct for difference in total 
cDNA amount. 
d. Add 2 µL of each diluted cDNA sample in triplicate to microtube 
strips. 
e. Add 23 µL of Master Mix to all wells. 
f. Close wells and place in Applied Biosystems StepOne Plus qPCR 
machine. 
g. Set the StepOne Plus application for a reaction volume of 25 µL, 
SYBR® Green Technology, Normal (~2.5 hour) Reaction Speed, and 
Include a Melt Curve Analysis. 
2.  ∆∆Ct Analysis 
a. After the run is complete. Confirm that the automatically determined 
thresholds are in the exponential amplification phase for each gene of 
interest. Export all data to an Excel spread sheet. 
b. Obtain the cycle number where the sample’s amplification plot crosses 
the defined threshold (i.e. the Ct value). 
c. Average the two closest Ct values. 
d. To determine the ∆Ct take the difference between the Ct value of the 
gene of interest and the Ct value of your housekeeping gene. Raise this 
to the power of two (i.e. 2∆Ct) and use this to compare differences in 
gene expression. 
e. To determine find the fold change in the gene expression from your 
control samples take the ∆Ct of each sample and subtract the ∆Ct of 
the control sample. Use these values (∆∆Ct) to generate a graph of 
gene expression relative to your control condition. 
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Flow Cytometry 
Reagents: 
• 100 nM Tetramethylrhodamine Ethyl Ester (TMRE) 
• 100 µM Dichlorodihydrofluorescein Diacetate (H2DCFDA) 
• 100 nM MitoTracker Green FM (MTGFM) 
• 200 nM LysoTracker Red (LTR) 
• Phenol Red Free Complete Growth Medium 
o DMEM – Phenol Red Free 
o 10% FBS 
o 1% Penicillin-Streptomycin 
• Complete Growth Medium 
o DMEM 
o 10% FBS 
o 1% Penicillin-Streptomycin 
• 5 mL polystyrene round-bottom tube with cell strainer  
BD Falcon – REF 352235 
• 5 mL polystyrene round-bottom tube 
BD Falcon – REF 352052 
• Sheath Fluid 
BDFACS Flow - 342003 
Procedure: 
1. Preparation 
a. Plate cells in 5 - 75 cm2 tissue culture treated flasks. 
b. Allow a minimum of 24 hours for cells to adhere to the flask. 
2. Analysis 
a. Prepare all reagents. 
b. Aspirate all media from each flask 
c. Apply 5 mL of the staining solutions above to separate flasks for 45 
minutes. Include an unstained control. 
d. After staining, remove media and rinse flasks with DPBS. 
e. Incubate flasks for 5 minutes with trypsin. 
f. Triturate cell suspensions with Complete Growth Medium and place in 
previously labelled screw top plastic tubes. 
g. Centrifuge tubes at 1400 RPM for 3 minutes. 
h. Aspirate supernatant fraction without disturbing the pellet. 
i. Aliquot 400 µL of Phenol Red Free Complete Growth Medium to each 
tube. 
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3. Flow Cytometry 
a. Clean the BD FACSCalibur as per standard laboratory practices. 
b. Apply the following settings to the BD FACSCalibur. 
c. Immediately before reading each sample, gently resuspend each pellet 
and filter through a cell strainer capped 5 mL polysterene round-
bottom tube. 
d. Place the 5 mL tube on the SIP of the BD FACSCalibur. Wait until the 
sample voltage has reached 6.25V and start collection. Collect a 
minimum of 25,000 events for each sample. 
e. Remove sample and place a 5 mL tube containing pure sheath fluid on 
the SIP. 
f. Repeat steps c and d for each sample. 
g. Clean BD FACSCalibur as per standard laboratory practices.   
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Fluorescence Microscopy  
Reagents: 
• 100 nM MitoTracker Green FM (MTGFM) 
• 200 nM LysoTracker Red (LTR) 
• 2.5 µg/mL DAPI 
• Phenol Red Free Complete Growth Medium 
o DMEM – Phenol Red Free 
o 10% FBS 
o 1% Penicillin-Streptomycin 
Procedure: 
1. Staining 
a. Following treatment, remove medium. 
b. Apply 1.5 mL of Staining Solution for 40 minutes under normal cell 
growth conditions. 
c. Following 40 minutes at 15 µL of DAPI staining solution for 5 
minutes. 
d. Remove Staining Solution and incubate cells with 2 mL of Phenol Red 
Free Complete Growth Medium 
2. Microscopy 
a. Warm incubator to 37ºC and open valve from gas cylinder to obtain a 
gas flow of 100 mL/min. 
b. Change to the 100x objective and apply 1-3 drops of immersion oil. 
c. Open SimplyPCI. 
d. Change Profile to “Alex MTG-LTR-DAPI” 
e. Change to “Three Color Image” in the Capture window. 
f. Open “Filter Setup…” and confirm that there will be a pause 
following each exposure to allow you to manually change the 
emission filters. 
g. Change the settings to those below 
Channel Filter Offset Gain Exposure (s) 
Red TRITC 0 255 0.4 
Green FITC 0 255 0.1 
Blue DAPI 0 255 0.05 
  
h. Move the FITC emission filter into place. 
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i. Select “Focus” in the Capture window. Raise the objective into place 
and bring the cell into focus. Do this rapidly to avoid photobleaching. 
j. Select “Cancel.”  
k. Move the TRITC emission filter into place.  
l. Then select “Capture 1.” 
m. When the prompt appears, select “OK.” 
n. When the following prompt appears, move the “FITC” excitation into 
place and select “OK.” 
o. When the following prompt appears, move the “DAPI” excitation into 
place and select “OK.” 
p. Save the multicolour photo and record the settings used. 
q. Obtain a minimum of 40 photos per condition. Try to obtain pictures 
of only cells that are not touching. 
3. Analysis 
a. Use ImageJ to turn off the Blue channel. 
b. Increase the Green or Red channels as required. 
c. Count the distinct Red punctae and any Green punctae that are co-
localized with Red punctae. Record the counts. 
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Lactate Analysis 
Part A: Preparation of Deproteinized Samples 
Reagents: 
• 70% HClO4 (Perchloric Acid) 
• 2 N KOH 
• Cold PBS 
Procedure: 
1. Remove ~ 1000 µL of cell culture medium and place in a prelabeled 
eppendorf. 
2. Centrifuge eppendorf at 1.4 RPM for 3 minutes. 
3. Transfer 500 µL of the supernatant fraction to a new eppendorf and flash 
freeze in liquid nitrogen. Store at -80ºC until ready for further processing. 
4. Thaw samples quickly and transfer 100 µL of cell culture medium to a new 
eppendorf and refreeze remaining medium. 
5. Add 16.3 µL of cold 70% HClO4 to the 100 µL of cell culture medium. 
Immediately, add 80 µL of PBS and vigorously vortex. 
6. Incubate sample on ice for 10 minutes. 
7. Centrifuge samples for 5 minutes at max speed (14,000g) at 4ºC. 
8. Add 110.4 µL of cold 2 N KOH and vortex vigorously. 
9. Incubate on ice for 3 minutes and repeat step 7. 
10. Carefully, transfer the supernatant fraction to a new eppendorf and store the 
deproteinized samples at -20ºC for future analysis. 
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Part B: Lactate Assay 
Reagents: 
• Lactate Assay Kit I – Sigma Aldrich (MAK064-1KT) 
o 100 nmole/µL Lactate Standard 
o Lactate Assay Buffer 
o Lactate Enzyme Mix 
o Lactate Probe 
• Clear bottom, black walled 96-well plate 
Procedure: 
1. Bring all reagents to room temperature. 
2. Dilute Lactate Probe 1:10 in warm Lactate Assay Buffer to reduce 
background. 
3. Reconstitute Lactate Enzyme Mix by adding 220 µL of Lactate Assay Buffer 
and vigorous pipetting. 
4. Dilute 1 nmole/µL Lactate Standard 100x in Lactate Assay Buffer to make a 1 
nmole/µL Lactate Standard. Dilute 1 nmole/µL 10x in Lactate Assay buffer to 
make a 0.1 nmole/µL Standard. 
5. Create reaction Master Mix (50 µL required per well). 
Master Mix 1x 
Lactate Assay 
Buffer 46 
Lactate Enzyme 
Mix 2 
Lactate Probe 2 
6. Add 0.1 nmole/µL Lactate Standard and Lactate Assay Buffer in duplicate to 
wells as outlined below. 
Lactate 
Standard 
0.1 nmole/µL 
Lactate 
Standard 
Lactate Assay 
Buffer 
0 0 50 
0.2 2 48 
0.4 4 46 
0.6 6 44 
0.8 8 42 
1 10 40 
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7. For deproteinized cell culture medium, add 5 µL of deproteinized sample and 
45 µL of Lactate Assay Buffer in duplicate for each sample. 
8. Apply 50 µL of Master Mix to each well and mix thoroughly using a pipette 
and with an orbital shaker. 
9. Protect reaction plate from light and incubate for 30 minutes at room 
temperature. 
10. Use a microplate reader to assess absorbance at 570 nm for each well. Use the 
standard curve to assay the amount of lactate in each well. To ascertain the 
concentration of lactate in each sample, divide by the volume of sample in 
each well (for cell culture medium: 5 µL). 
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Western Blot Procedure 
Part A: Protein Extraction 
Reagents: 
• Complete Growth Medium 
o DMEM 
 With Glutamine 
 With 1 mM Sodium Pyruvate 
 With 50 µg/mL Uridine 
o 10% FBS 
o 1% Penicillin – Streptomycin 
• DPBS without Ca2+ or Mg2+ 
• Passive Lysis Buffer (PLB; for 1 mL): 
o 200 µL 5x Passive Lysis Buffer 
o 427.5 µL of ddH2O 
o Protease Inhibitors: 
 2 µL of 5 mg/mL Leupeptin 
 1 µL of 1 mg/mL Pepstatin A 
 1 µL of 10 mg/mL Aprotinin 
 1 µL of 1 M Dithiothreitol (DTT) 
 5 µL of 100 mM Phenylmethylsulfonyl fluoride (PMSF) 
• Made in isopropanol. 
• Add fresh each time because extremely unstable in 
aqueous solution. 
o Phosphatase Inhibitors 
 12.5 µL of 200mM Sodium Orthovanadate (Na3VO4) 
 100 µL of 500 mM Sodium Fluoride (NaF) 
 250 µL of 200 mM ß-Glycerolphosphate (ß-GP) 
Procedure: 
1. Grow cells in one 175 cm2 tissue culture flask. 
2. Pour off media. Wash with 5 mL DPBS. Aspirate DPBS. Add 5 mL of 0.25% 
Trypsin with EDTA and incubate at 37ºC for 5 minutes. 
3. Tap flask to disturb any adherent cells. Confirm detachment with a light 
microscope. 
4. Add 5 mL of complete growth media to inhibit trypsin. Use cell suspension to 
rinse the culture surface to remove any additional cells. 
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5. Transfer the cell suspension to a 15 mL conical tube and spin for 3 minutes at 
1400 RPM. 
6. Aspirate the supernatant fraction and resuspend the pellet in 1 mL of DPBS. 
7. Transfer the cell suspension to an eppendorf and spin the cells for another 3 
minutes at 1400 RPM. 
8. Aspirate the DPBS and add 100 µL of PLB. 
9. Vigorously vortex and flash freeze eppendorf in liquid nitrogen. Store at -
80ºC until ready for analysis 
10. To continue, remove the eppendorf and thaw at 37ºC. Immediately, vortex 
vigorously for 5 seconds. Freeze in liquid nitrogen and repeat 3 times. Thaw 
the cells one last time and vortex vigorously. 
11. Spin in microcentrifuge at 4 oC for 5 min at 13.0 rpm. 
12. Remove the supernate and add it to a new-labelled eppendorf tube. 
13. Freeze samples at -80ºC for protein quantification using the Bradford assay. 
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Part B: SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) – Bio-Rad Mini 
Protein System 
Reagents: 
• Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop 10.502) 
o Store at 4°C 
• Under Tris Buffer 
o 1M Tris-HCl, pH 8.8 (60.5g/500ml) 
o Store at 4°C 
• Over Tris Buffer 
o 1M Tris-HCl, pH 6.8 (12.1g/100ml) 
o Bromophenol Blue (for colour) 
o Store at 4°C 
• Ammonium Persulfate (APS) 
o 10% (w/v) APS in ddH20 (1g/10ml) 
o Store at 4°C 
• Sodium Dodecyl Sulfate (SDS) 
o 10% (w/v) in ddH20 (1g/10ml) 
o Store at room temperature 
• TEMED (Sigma T-9281) 
• Electrophoresis Buffer, pH 8.3 (10L) 
o 25mM Tris 30.34g, 192mM Glycine 144g, 0.1% SDS 10g 
o Volume to 10L with ddH20 
o Store at room temperature 
• 2 x Lysis Buffer 
• tert-Amyl alcohol ReagentPlus, 99% (Sigma 152463) 
Procedure: 
1. Prepare Mini-Protean gel caster system: 
a. Assemble glass plates as shown below:  
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2. Check the seal by adding a small volume of ddH20 then pour off and let dry.  
3. Make a mark 2 cm below the top edge of the short plate. This will indicate 
how high to fill the separating gel. 
4. Prepare separating gels: 
 
Mini Protean 3 Bio-Rad System volumes 
Separating Gel 8 % 10 % 12 % 15 % 18 % 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
Water 4.1 ml 3.5 ml 2.8 mL 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100 µl 100 µl 100 µl 100 µl 100 µl 
APS 100 µl 100 µl 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 10 µl 
 
a. Mix the contents of the separating gel without TEMED.  
b. Add TEMED. Briefly stir. Immediately, pour the contents between the 
short and spacing plates until the volume reaches 2 cm from the top 
edge of the short plate 
c. Coat the top surface of the gel solution with tert-Amyl alcohol to 
remove any bubbles. 
d. Allow 10 - 30 minutes for gel polymerization.  
e. Remove tert-Amyl alcohol by pouring it off and remove any 
remainder with a scrap piece of Whatman paper. 
5. Prepare stacking gel: 
a. For a single mini gel use the following volumes: 
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Stacking Gel (3% 
Acrylamide) 1 Mini Gel 
Acrylamide 250 µL 
Water 1.875 mL 
Above Tris buffer 312.5 µL 
SDS 25 µL 
APS 25 µL 
TEMED 10 µL 
 
b. Mix the contents of the stacking gel without adding TEMED. Stir.  
c. Add TEMED. Stir and pour the stacking gel on top of the polymerized 
separating gel.  
d. Immediately, add the appropriate comb for desired number of wells 
and thickness of spacer plate. 
e. Allow 10 - 30 minutes for gel polymerization. 
f. Gels may be used immediately or stored in a wet sealed container at 
4ºC.  
6. Prepare samples: 
a. Warm block heater to 95ºC.  
b. Pipette the appropriate volume of each sample into a new eppendorf. 
This volume is determined by the protein concentration assessed using 
the Bradford assay and the required amount of protein required for 
the detection of the desired protein. 
c. Add an equal amount of 2X Lysis Buffer supplemented with 5% B-
Mercaptoethanol. Add 5 µL of Sample Dye to each sample. 
d. Briefly spin each sample to bring volume to the bottom of the 
eppendorf. 
e. Incubate each sample at 95ºC for 5 minutes in the heating block to 
denature the proteins.  
f. Briefly spin again to return volume to the bottom of the eppendorf. 
 
7. Assemble Mini-Protean electrophoresis rack: 
a. See images below: 
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b. If you are only running one gel a plastic rectangular pseudo plate must 
be clamped on the other side of the caster.  
c. Fill the middle chamber of the electrophoresis apparatus with 
Electrophoresis Buffer. Fill the outer chamber with Electrophoresis 
Buffer, until the level is approximately 2 cm above the bottom of the 
gels.  
d. Slowly remove the comb using both hands (one on each side) by 
pulling the comb straight upwards.  
e. Fix any wells that are deformed using a pipette tip.  
f. Clean out the wells using a pipette tip and Electrophoresis Buffer. 
g. Apply 10 µL of protein ladder to the first well.  
h. Withdraw the entire volume of the sample using a gel-loading tip. 
Inject the solution slowly into the bottom of the well.  
 
8. Gel Electrophoresis: 
a. After all samples are loaded, immediately, place the lid on the gel 
chamber. 
b. Place the positive and negative leads into the power supply. 
c. Use a power supply to apply a constant voltage of 90V across the gel. 
After the bromophenol blue has passed the border between the 
stacking and separating gel, increase the voltage to 120V for 60 – 120 
minutes until sufficient separation has been achieved as indicated by 
the protein ladder. 
d. Prepare for electrotransfer of proteins from the gel to nitrocellulose 
membrane.  
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Part C: Western Blotting and Immunodetection 
Reagents: 
• Transfer Buffer 
o 0.025M Tris-HCl pH 8.3   12.14g 
o 0.15M Glycine    45.05g 
o 20% Methanol   800ml 
o Make 4L with ddH20 
o Store at 4°C 
• Ponceau S stain 
o 0.1% (w/v) Ponceau S  
o 0.5% (v/v) Acetic Acid 
o Store at room temperature 
• Wash Buffer 
o Tris-HCl pH 7.5    12g 
o NaCl    58.5g 
o 0.1% Tween   10ml 
o Store at room temperature 
• Blocking Buffer 
o 5% (w/v) skim milk power in Wash Buffer 
• Enhanced Chemiluminescence Fluid (ECL; Santa Cruz - SC-2048) 
• Film Developer and Fixer 
Procedure: 
1. Transfer Procedure 
a. Using a paper cutter cut 6 pieces of Whatman paper per gel. Each 
piece should measure 8.5 cm x 6 cm. Wearing gloves cut an 8.5cm x 6 
cm piece of nitrocellulose membrane (GE Healthcare RPN303D). 
Soak Whatman paper and nitrocellulose membrane in Transfer Buffer 
until use. 
b. Remove electrophoresis plates from chamber and separate the plates. 
c. Remove stacking gel 
d. Assemble Whatman paper, nitrocellulose membrane and gel as shown 
below, ensuring that the gel and membrane are orientated so that the 
gel is closer to the black surface and the membrane closer to the white 
plastic clamp. 
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e. Close the cassette and place in the transfer chamber with the black side 
of the cassette facing the negative electrode (black side) of the 
chamber.  
f. Place an ice pack and magnetic stir bar in the chamber. 
g. Place the chamber in a Tupperware container. Place the container on 
top of a magnetic stir plate. Turn on the stir plate and ensure the 
magnetic stir bar is spinning. 
h. Fill the chamber completely with cold Transfer Buffer. Place lid on the 
chamber and connect the leads to a power supply.  
i. Turn on the power supply and apply a constant voltage of 120V for 
1.5 hours. This can vary depending on the size of the protein of 
interest. 
2. Removal of nitrocellulose membrane: 
a. Turn off the power supply and disconnect leads from the power supply. 
b. Remove the cassette from the chamber.  
c. While wearing gloves, carefully dispose of the Whatman paper and gel. 
d. Gently place the nitrocellulose membrane in a plastic dish and apply 
Ponceau S stain for 5 minutes.  
e. Drain off the remaining Ponceau S and save for reuse. 
f. Rinse the membrane 3-5x with ddH2O to reduce the red background. 
Wrap membrane in saran wrap and scan. 
g. Cut the membrane while protein bands are still visible at the desired 
molecular weight. 
h. Rotate membrane at room temperature in Wash Buffer until remaining 
Ponceau S stain has been removed (~5 minutes). 
i. Incubate membrane for 1 hour with rotation in Blocking Buffer at 
room temperature.   
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3. Immunodetection 
a. Primary Antibody Incubation 
i. Wrap a flat piece of glass in parafilm. Place the glass in a 
Pyrex dish. Arrange balls of wet tissue around the dish and 
cover the entire dish with saran wrap. 
ii. Place the dish in a 4ºC fridge and level. 
iii. Place nitrocellulose membrane strips face up on the flat 
parafilm surface. 
iv. Dilute the primary antibody raised against the protein of 
interest in Blocking Buffer. Gently apply ~1-1.5 mL of diluted 
antibody overtop of the appropriate membrane strip. 
v. Specific antibody dilutions used in this study are listed at the 
end of this protocol. 
b. Secondary Antibody Incubation 
i. Wash the blots in Wash Buffer with gentle rotation for 5 
minutes 3X. 
ii. Incubate the blots as described in step 3.a with the following 
changes. Incubate the blots for 1 hour with a secondary 
antibody raised against the species and specific 
immunoglobulin molecule of the primary antibody. Incubate at 
room temperature. 
c. Following the incubation, wash the membrane 3X for 5 minutes with 
Wash Buffer. 
4. Enhanced Chemiluminescence Detection 
Note: Complete the following steps in a dark room sufficient for 
photographic film developing. 
a. Mix ECL fluids “A” and “B” in a 1:1 ratio in a small plastic box. 
b. Place blots facedown in the small plastic box and place on a level 
surface. Some swirling may be required to ensure equal coverage. 
c. Following 2 minutes, remove blots and place face down on clean Kim 
wipes to remove excess ECL fluid. 
d. Place membrane strips on clean overhead transparency film and 
remove any bubbles. 
e. Turn off any lights. 
f. Place membrane strips face up in a film cassette.  
g. Momentarily cover the strips with cardboard while cutting pieces of 
film to the approximate size of the membrane strips. 
h. Remove the film and apply film overtop of the membrane strips. Do 
not move the film once it has been placed on top of the membrane. 
i. Close the cassette and expose the film for the desired time.  
j. After the exposure time, remove the film and place the cassette aside. 
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k. Attach the film to a film hanger and dip 5-6x in film developing 
solution. 
l. Hold the film up to a red light. When bands become apparent, 
immediately submerge the film in water and then in the film fixing 
solution for 5 minutes. 
m. Following 5 minutes in the fixing solution, the film can then be 
submerged in water and attached to butterfly binder clips to dry. They 
are no longer light sensitive. 
 
Protein 
of 
Interest 
% Gel Loaded 
Protein 
Mass 
Protein 
Mass 
Primary 
Antibody 
Primary 
Antibody 
Dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
Exposure 
Time 
Ρ-AMPK 12 25 µg 62 kDa Cell 
Signalling  
1:1000 in 
5% BSA 
Santa Cruz 
anti-Rabbit 
IgG 
1:1000 in 
5% Skim 
Milk 
~ 30 s 
T-AMPK 12 25 µg 62 kDa Cell 
Signalling 
1:1000 in 
5% Skim 
Milk 
Santa Cruz 
anti-Rabbit 
IgG 
1:1000 in 
5% Skim 
Milk 
~ 60 s 
LC3 15 50 µg 12 and 
18 kDa 
Cell 
Signalling 
1:250 in 
5% Skim 
Milk 
Santa Cruz 
anti-Rabbit 
IgG 
1:1000 in 
5% Skim 
Milk 
~ 15 s 
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Whole Cell Respiration Procedure 
Part A: OxoPlate Respiration 
Adapted from OxoPlate Manual and Nicholls 
Reagents and Disposables Required: 
• 96-well Flat Bottomed OxoPlate – OP96C 
Manufacturer – PreSens (http://www.presens.de/) 
North American Distributor – Innovative Instruments Inc.  
(http://www.3i-usa.com/) 
• 0% O2 Standard 
o Add 150mg of sodium sulfite (Na2SO3) to a 15 mL screw top tube. 
o Add 15 mL of ddH2O and seal tube 
o Vortex and allow >1 minute for oxygen to be depleted from solution 
Notes: 
 Must use a screw top lid and use enough ddH2O to almost 
entirely fill container. This will minimize any dissolving of O2 
from the air in the tube. 
 DO NOT REPLACE ddH2O with Growth Media 
 Shelf life is ~24 hours 
• 100% O2 Standard 
o Aliquot 7.5 mL of Phenol Red Free Growth Media into a 15 mL screw 
top tube. 
o Shake vigorously for 2 minutes. 
o Loosen screw top and gently rotate tube to decrease foaming and 
prevent oversaturation of solution. 
Notes: 
 Shelf life is ~24 hours 
• Grow Medium 
o DMEM – Phenol Red Free 
o 10% FBS 
o 1% Penicillin-Streptomycin 
• Oligomycin 
Sigma O4876 
Mixture 65% Oligomycin A – MW: 791 
Remainder: 
o Oligomycin B – MW 805.1 
o Oligomycin C – MW: 775.1 
Average MW: 790.685 
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o Final Concentration: 1 µM 
o Stock Solution: 300 µM in DMSO 
o Serial Dilutions: 
 1 mg in 1 mL DMSO = 1.265 mM 
 237.15 µL of 1.265 mM in 762.85 µL DMSO = 300 µM 
o Working Solution: 
 Aliquot 12 mL Phenol Red Free Growth Medium  
 Remove 40 µL 
 Add 40 µL of 300 µM Oligomycin 
• Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) 
Sigma C2759 
MW: 204.62 
o Final Concentration: 3 µM 
o Stock Solution: 900 µM in DMSO 
o Serial Dilutions: 
 2.0462 mg in 1 mL DMSO = 10 mM 
 90 µL of 10 mM in 910 µL DMSO = 900 µM 
o Working Solution: 
 Aliquot 12 mL Phenol Red Free Growth Medium  
 Remove 40 µL 
 Add 40 µL of 900 µM CCCP 
• Rotenone 
Sigma R8875 
MW: 394.42 
o Final Concentration: 2 µM 
o Stock Solution: 600 µM in DMSO 
o Serial Dilutions: 
 3.9442 mg in 1 mL DMSO = 10 mM 
 60 µL of 10 mM in 940 µL DMSO = 600 µM 
• Antimycin A 
Sigma A8674 
MW: 548.63 
o Final Concentration: 2 µM 
o Stock Solution: 600 µM in DMSO 
o Serial Dilutions: 
 5.4963 mg in 1 mL DMSO = 10 mM 
 60 µL of 10 mM in 940 µL DMSO = 600 uM 
• Rotenone and Antimycin A Working Solution 
o Working Solution: 
 Aliquot 12 mL Phenol Red Free Growth Medium  
 Remove 80 µL 
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 Add: 
• 40 µL of 600 µM Rotenone 
• 40 µL of 600 µM Antimycin A 
• Dimethyl Sulfoxide (DMSO) 
o Working Solution: 
 Aliquot 12 mL Phenol Red Free Growth Medium  
 Remove 40 µL 
 Add 40 µL of DMSO 
Procedure: 
1. Initial Day: 
a. All conditions must be performed in triplicate. 
b. Perform all work in darkness and protect the OxoPlate from light at all 
times. 
c. Plate a sufficient number of cells to acquire a minimum of 8,000 
cells/well when measuring oxygen consumption. 
i. DO NOT PLATE CELLS IN WELLS FOR STANDARDS. 
ii. A sample seeding plan is included below. 
d. Cover plate, protect from light, and incubate. 
e. Incubate long enough for cells to adhere (recommended 24 hours). 
2. Respiration Day: 
a. Prepare standards (0% O2 Standard and 100% O2 Standard). 
b. Warm all cell culture media and drugs. 
c. Make working solutions. 
d. Aliquot 400 µL of each solution into the relevant wells of a second 
sterile 96-well plate. 
e. Place the plate containing the experimental media in an incubator 
close to plate reader and warm to 37ºC. 
f. Make 0% and 100% solutions and warm to 37ºC. 
g. Prepare another plate with > 75 µL of mineral oil and warm to 37ºC. 
h. Gently aspirate all media from the OxoPlate 
i. Add 350 µL of the 0% standard in triplicate to the appropriate 
OxoPlate wells. 
j. Add 250 µL of the 100% standards in triplicate to the OxoPlate wells. 
k. Rapidly, use a multichannel pipette to transfer 350 µL of warm media 
from the warmed plate to the OxoPlate. 
l. Rapidly, use a multichannel pipette to overlay the OxoPlate wells with 
50 µL of warm mineral oil. 
m. Further seal the plate with clear transparent PCR plate sealing film. 
n. Immediately read on fluorescent plate reader with the parameters 
listed below. 
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3. If required, correct for differences in cell number (part B) 
Fluorescence Plate Reader Settings: 
• Reading Type: Kinetic 
• Reader: Synergy HT-I on: Fluorescence 
• Filer Set: 2 
• Excitation: 530/25 (for both) 
• Emission: 645/40 and 590/35 
• Optics Position: Bottom (for both) 
• Sensitivity: 50 (for both) 
• Click Options (same for both) 
o Nb Samples per Well: 20 – Can decrease reading time by reducing 
this number 
o Delay before Sampling: 300 msec – Can decrease reading time by 
reducing this number 
o Delay between samples: 1 msec 
• Select: Kinetic… 
o Run Time: 03:00:00 
o Click Minimum 
o Interval should be 00:02:51 with above settings 
o Check Allow Well Zoom during read 
• Temperature Control: Yes 
• Check Pre-Heating 
• Temperature: 37ºC 
• Lag time: 00:00:00 
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Sample Plate Layout 
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Part B: Cell Quantification 
Adapted from CyQuant Manual 
Reagents: 
• Life Technologies CyQuant Assay 
o 20x Cell-Lysis Buffer 
o CyQuant GR Dye 
• DEPC ddH2O 
• CyQuant Assay Buffer (for 25 mL) 
o 1250 µL of 20x Cell-Lysis Buffer 
o 23687.5 µL of DEPC ddH2O 
o 62.5 µL of CyQyant GR Dye 
Procedure: 
1. Generate Cell Number Standard 
a. Grow control cells under normal conditions. 
b. Rinse cells with DPBS without Calcium and Phosphorus 
c. Apply Trypsin with 0.25% EDTA for 5 minutes at 37ºC 
d. Triturate cell suspension with equal volumes of complete growth 
medium. 
e. Centrifuge the cell suspension in a screw cap tube at 1400 RPM for 3 
minutes. 
f. Remove the supernate and triturate the pellet in 1-1.5 mL of DPBS. 
g. Carefully determine the cell concentration with a hæmocytometer. 
h. Aliquot 1 mL of the cell suspension in a sterile eppendorf and 
centrifuge the eppendorf at 1400 RPM for 3 minutes. 
i. Remove the supernate and freeze at -80ºC. 
j. Add a volume of CyQuant Assay Buffer to generate a solution with a 
cell concentration of 1 x 106 cells/mL. 
2. Prepare OxoPlate 
a. Gently remove media from the OxoPlate by inverting the plate and/or 
careful aspiration of the media. 
b. Freeze the OxoPlate at -80ºC 
3. Analyze OxoPlate 
a. Add the following amount of the standard and CyQuant Assay Buffer 
to the standard wells (A1-A6) of the OxoPlate. 
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Cell 
Number  
Volume of 
Standard 
Volume of 
Buffer 
0 0 200 
10000 10 190 
20000 20 180 
30000 30 170 
40000 40 160 
50000 50 150 
 
b. Apply 200 µL of CyQuant Assay Buffer to each well. 
c. Mix vigorously with an orbital shaker. Protect from light and allow to 
react for 5 minutes. 
d. Read assay on microplate reader with the settings below. 
Fluorescence Plate Reader Settings: 
• Reading Type: Kinetic 
• Reader: Synergy HT-I on: Fluorescence 
• Filer Set: 1 
• Excitation: 530/25 
• Emission: 645/40 and 590/35 
• Optics Position: Bottom 
• Sensitivity: 50 
• Click Options 
o Nb Samples per Well: 20 
o Delay before Sampling: 300 msec 
o Delay between samples: 1 msec 
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